<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        251-11-06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2006
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CERTICAN 0.5MG TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        EVEROLIMUS
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        766.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance of Certican is everolimus.</p><p>Everolimus belongs to a group of medicines called immunosuppressants. It is used in adults to prevent the body&rsquo;s immune system from rejecting a transplanted kidney, heart or liver. Certican is used together with other medicines, such as ciclosporin for kidney and heart transplantation, tacrolimus for liver transplantation, and corticosteroids. <strong>&nbsp;&nbsp; </strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a.&nbsp;&nbsp;&nbsp;&nbsp; Do not take Certican</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic (hypersensitive) to everolimus or any of the other ingredients of this medicine (listed in section 6).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic (hypersensitive) to sirolimus.</p><p>&nbsp;</p><p><strong>If any of the above applies to you, tell your doctor and do not take Certican.</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take special care with Certican</strong></p><p><strong>Talk to your doctor before taking Certican: </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that suppress the immune system like Certican reduce your body&acute;s ability to fight against infections. It is advisable to consult your doctor or transplant centre if you have a fever or generally feel unwell or have local symptoms such as coughing or a burning sensation when urinating that are severe or persistent over several days. Consult your doctor or transplant centre right away if you feel confused, have problems speaking, memory loss, a headache, impaired vision or seizures, as these may be symptoms of a rare but very serious condition called progressive multiple leukoencephalopathy (PML).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had recent major surgery, or if you still have an unhealed wound following surgery, Certican may increase the risk of wound-healing problems.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that suppress the immune system like Certican increase the risk of developing cancers, particularly of the skin and the lymphoid system. Therefore, you should limit your exposure to sunlight and UV light by wearing appropriate protective clothing and frequently applying a sunscreen with a high protection factor.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will monitor your kidney function, the amounts of fats (lipids) and sugar in your blood as well as the amount of proteins in your urine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have liver problems or have ever had a disease which may have affected your liver, please tell your doctor. Your doctor may need to modify the dose of Certican you are taking.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience respiratory symptoms (e.g. coughing, difficulty in breathing and wheezing), please inform your doctor. Your doctor may decide whether and how you need to continue Certican, and/or whether you need to receive other medicines to resolve this condition.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certican may reduce sperm production in men, thereby reducing the ability to father children. The effect is generally reversible. Male patients wanting to father children should discuss their treatment with their physician.</p><p>&nbsp;</p><p><strong>Older people (65 years and over) </strong></p><p>There is limited experience with the administration of Certican in elderly people.</p><p>&nbsp;</p><p><strong>Children and adolescents (younger than 18 years of age)</strong></p><p>Certican should not be used in children and adolescents with a transplanted kidney, heart or liver.</p><p>&nbsp;</p><p><strong>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Other medicines</strong><strong> and Certican</strong></p><p>Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p>Certain medicines may affect the way in which Certican works in the body. It is very important that you tell your doctor if you are taking any of the following medicines:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; immunosuppressive medicines other than ciclosporin, tacrolimus or corticosteroids.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antibiotics, such as rifampicin, rifabutin, clarithromycin, erythromycin or telithromycin.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antiviral medicines, such as ritonavir, efavirenz, nevirapine, nelfinavir, indinavir or amprenavir, which are used to treat HIV infection.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat fungal infections, such as voriconazole, fluconazole, ketoconazole or itraconazole.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat epilepsy, such as phenytoin, phenobarbital or carbamazepine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat high blood pressure or heart problems, such as verapamil, nicardipine or diltiazem.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dronedarone, a medicine used to help regulate your heart beat.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to lower blood cholesterol, such as atorvastatin, pravastatin or fibrates.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat acute seizures, or used as a sedative before or during surgery or other medical procedures, such as midazolam.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cannabidiol (uses amongst others include treatment of seizures).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; octreotide, a medicine used to treat acromegaly, a rare hormonal disorder that usually occurs in middle-aged adults.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; imatinib, a medicine used to inhibit the growth of abnormal cells.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s wort (<em>Hypericum perforatum</em>), a herbal medicine used to treat depression.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you need to have a vaccination, talk to your doctor first.</p><p>d. Taking Certican with food and drink</p><p>The presence of food can affect how much Certican is absorbed. In order to keep constant levels in your body, you should always take Certican in the same way. You should either always take it with food, or always on an empty stomach.</p><p>&nbsp;</p><p>Do not take Certican with grapefruit juice or grapefruit. They affect how Certican works in the body.</p><p>&nbsp;</p><p>e. Pregnancy, breast-feeding and fertility</p><p>If you are pregnant, do not take Certican unless your doctor thinks it is absolutely necessary. If you are a woman and you could get pregnant, you should use an effective method of contraception during treatment with Certican and for 8 weeks after stopping treatment.</p><p>&nbsp;</p><p>If you think you may be pregnant, ask your doctor or pharmacist for advice before taking Certican.</p><p>&nbsp;</p><p>You should not breast-feed while taking Certican. It is not known whether Certican passes into breast milk.</p><p>&nbsp;</p><p>Certican may have an impact on male fertility.</p><p>&nbsp;</p><p><strong>f. Driving and using machines </strong></p><p>No studies on the effects on the ability to drive and use machines have been performed.</p><p>g. Important information about some of the ingredients of Certican&nbsp;</p><p>Certican tablets contain lactose. If you do not tolerate certain sugars (glucose, galactose, lactose), you should talk to your doctor before taking Certican.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor will decide exactly what dose of Certican you should take and when you should take it.</p><p>&nbsp;</p><p>Always take Certican exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>How much to take</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual starting dose is 1.5 mg/day in kidney and heart transplantation and 2.0 mg/day in liver transplantation. &nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This is usually divided into two doses, one in the morning and one in the evening.</p><p>&nbsp;</p><p>How to take Certican</p><p>Certican should only be taken by mouth.</p><p>Do not crush the tablets.</p><p>Swallow the tablets whole with a glass of water.</p><p>You should take the first dose of this medicine as early as possible after kidney and heart transplantation and approximately four weeks after liver transplantation.</p><p>You should take the tablets together with ciclosporin for microemulsion in kidney and heart transplantation, and with tacrolimus in liver transplantation.</p><p>Do not switch from Certican tablets to Certican dispersible tablets without first telling your doctor.</p><p>&nbsp;</p><p>Monitoring during your treatment with Certican</p><p>Your doctor may adjust your dose depending on how much Certican there is in your blood and depending on how well you respond to the treatment. Your doctor will perform regular blood tests to measure the amount of everolimus and ciclosporin in your blood. Your doctor will also carefully monitor your kidney function, blood lipids and blood sugar, as well as the amount of proteins in your urine.</p><p>&nbsp;</p><p><strong>If you take more Certican than you should </strong></p><p>If you take more of this medicine than you should, talk to your doctor immediately.</p><p>&nbsp;</p><p>If you forget to take Certican</p><p>If you have forgotten to take your dose of Certican, take it as soon as you remember and then take the next dose at the usual time. Ask your doctor for advice. Do not take a double dose to make up for a forgotten tablet.</p><p>&nbsp;</p><p>If you stop taking Certican</p><p>Do not stop taking the tablets unless your doctor tells you to. You will need to take this medicine for as long as you need to have immunosuppressants to prevent the rejection of your transplanted kidney, heart or liver. If you stop taking Certican, you will have a greater risk of your body rejecting the transplanted organ.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Because you take Certican together with other medicines, it is not always clear whether the side effects are caused by Certican or by the other medicines.</p><p>&nbsp;</p><p><strong>The following side effects need immediate medical attention: </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lungs,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever and bruising under the skin that may appear as red dots, with or without unexplained tiredness, confusion, yellowing of the skin or eyes, reduced urine output (thrombotic microangiopathy, haemolytic uraemic syndrome).<strong> </strong></p><p>&nbsp;</p><p>Should you develop any of the following:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; persistent or worsening lung/breathing symptoms such as coughing, difficulty breathing, or wheezing,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, generally feeling unwell, chest or abdominal pain, chills, burning sensation when urinating,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of face, lips, tongue or throat,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty swallowing,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spontaneous bruising or bleeding for no obvious reason,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, unusual warmth, swelling or oozing from the site of surgery</p><p>&nbsp;</p><p>you should stop taking Certican and <strong>tell your doctor straight away</strong>.</p><p>&nbsp;</p><p><strong>Other reported side effects include: </strong></p><p>&nbsp;</p><p><strong>Very common</strong><em> (may affect more than 1 in 10 patients) </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections (viral, bacterial and fungal infections),</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lower respiratory tract infections, such as lung infections, including pneumonia</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory tract infections, such as inflammation of the pharynx, and common cold,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary tract infections,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaemia (reduced red blood cell count),</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of white blood cells, leading to a higher risk of infection, reduced blood platelet count, which can lead to bleeding and/or bruising underneath the skin,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high level of fats (lipids, cholesterol and triglycerides) in the blood, &nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; onset of diabetes (high level of sugar in the blood),</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced level of potassium in the blood,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems falling asleep (insomnia),</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fluid collection in the sac around the heart, which if severe, can decrease the heart&#39;s ability to pump blood,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; venous thrombosis (blockage of a major vein by a blood clot),</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fluid collection on the lungs and in the chest cavity, which, if severe, could make you breathless,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coughing,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathlessness,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea),</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being sick (vomiting),</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach (abdominal) pain,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; general pain,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; accumulation of fluid in the tissues,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal wound healing.</p><p>&nbsp;</p><p><strong>Common </strong><em>(may affect up to 1 in 10 patients)</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood poisoning,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wound infection,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cancers and benign tumours,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin cancer,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney damage with low blood platelets and low red blood cell counts, with or without a rash (thrombocytopenic purpura/haemolytic uraemic syndrome), &nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breakdown of red blood cells, &nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of red blood cells and platelets,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heart beat,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nose bleeds,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced numbers of blood cells (symptoms may include weakness, bruising and frequent infections),</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clotting in the blood vessels of the kidney, which may result in graft loss mostly within the first 30 days after kidney transplantation,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding disorders, &nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cyst containing lymph fluid, &nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the mouth or throat,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mouth sores,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acne, &nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives (urticaria) and other allergic symptoms, such as swelling of the face or throat (angiooedema),</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; protein in the urine,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney disorders,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impotence,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hernia at the site of surgery,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal liver test results,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; menstrual disorders (including absent or heavy periods).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Uncommon</strong><em> (may affect up to 1 in 100 patients)</em>:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cancer of the lymph tissue (lymphoma/post-transplant lymphoproliferative disorder),</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of testosterone,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lungs,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; jaundice,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ovarian cysts.</p><p>&nbsp;</p><p><strong>Other side effects</strong><em>:</em></p><p>Other side effects have occurred in a small number of people, but their exact frequency is unknown:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal accumulation of protein in the lungs (symptoms may include persistent dry cough, fatigue and difficulty breathing),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of blood vessels,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling, feeling of heaviness or tightness, pain, limited mobility of body parts (this could occur anywhere in the body and is a potential sign of an abnormal build-up of fluid in soft tissue due to a blockage in the lymphatic system, also known as lymphoedema),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe rash with skin swelling,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of iron in blood.</p><p>&nbsp;</p><p>If you have concerns regarding any of these effects, <strong>tell your doctor.</strong></p><p>&nbsp;</p><p>There may also be side effects of which you are not aware, such as abnormal results of laboratory tests, including tests of kidney function. This means that your doctor will perform blood tests to monitor any changes to your kidneys during your treatment with Certican.</p><p><em>&nbsp;</em></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep Certican out of the sight and reach of children.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&ordm;C.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Certican after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store the blister packs in the original carton in order to protect from light and moisture.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use any Certican pack that is damaged or shows signs of tampering.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is everolimus. Each tablet contains 0.25, 0.5 or 0.75 mg everolimus.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>- Certican 0.25 mg tablets: butylhydroxytoluene (E321), magnesium stearate, lactose monohydrate (2 mg), hypromellose, crospovidone and anhydrous lactose (51 mg).</p><p>-Certican 0.5 mg tablets: butylhydroxytoluene (E321), magnesium stearate, lactose monohydrate (4 mg), hypromellose, crospovidone and anhydrous lactose (74 mg).</p><p>-Certican 0.75 mg tablets: butylhydroxytoluene (E321), magnesium stearate, lactose monohydrate (7 mg), hypromellose, crospovidone and anhydrous lactose (112 mg).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Certican 0.25 mg tablets are white to yellowish, marbled, round, flat tablets of 6 mm, engraved “C” on one side and “NVR” on the other. 
•	Certican 0.5 mg tablets are white to yellowish, marbled, round, flat tablets of 7 mm, engraved “CH” on one side and “NVR” on the other. 
•	Certican 0.75 mg tablets are white to yellowish, marbled, round, flat tablets of 8.5 mm, engraved “CL” on one side and “NVR” on the other.

Certican tablets are supplied in packs containing 60 tablets. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p><u>www.Novartis.com</u>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                UK 06/2022 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">المادة الفعَّالة بعقار سيرتيكان هي إفيروليموس.</p><p dir="RTL">ينتمي إفيروليموس إلى مجموعة من الأدوية تُعرف بكابتات المناعة، وهو يُستَخدَم في البالغين؛ لمنع الجهاز المناعي للجسم من رفض العضو المزروع سواء كان كُلى أو قلبًا أو كبدًا. يُستَخدَم عقار سيرتيكان بمصاحبة أدوية أخرى، مثل سيكلوسبورين لعمليات زرع الكُلى والقلب، وتاكروليموس لعمليات زرع الكبد والكورتيكوستيرويدات.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول عقار سيرتيكان في الحالات الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية (حساسية مفرطة) تجاه إفيروليموس أو أيٍّ من المكونات الأخرى بهذا الدَّواء (المدرجة بالقسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية (فرط حساسية) تجاه سيروليموس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كان أيٌّ مما سبق ينطبق عليك، فأبلغ طبيبك ولا تتناول عقار سيرتيكان.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&zwnj;ب.&nbsp;&nbsp;&nbsp; </strong><strong>الاحتياطات عند استعمال عقار سيرتيكان</strong></p><p dir="RTL"><strong>تحدَّث إلى طبيبك قبل تناوُل عقار سيرتيكان: </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلل الأدوية التي تثبط الجهاز المناعي مثل عقار سيرتيكان من قدرة جسمك على مكافحة العدوى. يُنصَح باستشارة طبيبك أو مركز زراعة الأعضاء إذا أُصِبت بحُمى أو شعرت بتوعُّك بشكل عام، أو أُصِبت بأعراض موضعية شديدة أو مستمرة على مدار عدة أيام، مثل: السُّعال أو الإحساس بالحُرْقة عند التبوُّل. استشر طبيبك أو مركز زراعة الأعضاء فورًا إذا شعرت بالارتباك أو كان لديك مشاكل في التحدُّث أو فقدان للذاكرة أو صداع أو ضعف البصر أو نوبات تشنُّجية؛ إذ قد تكون هذه أعراض حالة نادرة ولكن خطيرة جدًّا تُسمى اعْتِلال بيضاء الدماغ متعدد البُؤَرِ المترقي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد خضعت مؤخرًا لجراحة كبرى، أو إذا كان لديك جرح بعد الجراحة لم يتم التئامه بعد، فقد يزيد عقار سيرتيكان من خطر حدوث مشاكل في التئام الجروح.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تزيد الأدوية التي تثبط الجهاز المناعي مثل عقار سيرتيكان من خطورة الإصابة بأمراض السرطان، لا سيَّما التي تصيب الجلد والجهاز اللمفاوي. لذا، يجب عليك الحد من التعرُّض لأشعة الشمس والأشعة فوق البنفسجية عن طريق ارتداء الملابس الواقية المناسبة والاستعمال المتكرر لأحد منتجات الوقاية من أشعة الشمس ذات عامل الوقاية المرتفع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيُراقِب طبيبك وظائف الكُلى لديك وكمية الدهون والسكر لديك في الدَّم وكذلك كمية البروتينات في البول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُصابًا بمشاكل في الكبد أو أُصِبت من قبل بمرض أثَّر على كبدك، فيُرجى إخبار طبيبك. قد يحتاج طبيبك إلى تعديل جرعة عقار سيرتيكان التي تتناولها.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بأعراض بالجهاز التَّنفسي (على سبيل المثال: سُعال، وصعوبة في التَّنفس وأزيز بالصدر)، فيُرجى إبلاغ طبيبك. قد يقرر طبيبك ما إذا كنت بحاجة إلى مواصلة العلاج بعقار سيرتيكان أم لا وكيفية القيام بذلك، و/أو ما إذا كنت بحاجة إلى تلقي أدوية أخرى للتَّعافي من هذه الحالة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يقلل عقار سيرتيكان إنتاج الحيوانات المنوية لدى الرجال، وبالتَّالي يقلل من القدرة على إنجاب أطفال. يكون هذا التَّأثير بشكل عام قابلًا للارتداد. يجب على المرضى الذكور الذين يرغبون في إنجاب أطفال مناقشة علاجهم مع أطبائهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأشخاص الأكبر سنًّا (بعمر 65 عامًا فأكبر) </strong></p><p dir="RTL">هناك خبرة محدودة بشأن تناوُل كبار السن لعقار سيرتيكان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون (دون سن 18 عامًا)</strong></p><p dir="RTL">يجب عدم استخدام عقار سيرتيكان في الأطفال والمراهقين ممن خضعوا لعملية زرع كُلى، أو قلب أو كبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ج.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تناوُل أدوية أخرى مع عقار سيرتيكان</strong></p><p dir="RTL">يُرجى إبلاغ الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى، بما في ذلك أية أدوية حصلت عليها دون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تؤثر بعض الأدوية على الطريقة التي يعمل بها عقار سيرتيكان في الجسم. من المهم جدًّا أن تخبر طبيبك إذا كنت تتناول أيًّا من الأدوية التَّالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الكابتة للمناعة بخلاف سيكلوسبورين أو تاكروليموس أو الكورتيكوستيرويدات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية، مثل: ريفامبيسين أو ريفابوتين أو كلاريثروميسين أو إريثروميسين أو تيليثروميسين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الفيروسات، مثل: ريتونافير أو إيفافيرينز أو نيفيرابين أو نيلفينافير أو إندينافير أو أمبرينافير، والتي تُستَخدَم لعلاج عدوى فيروس نقص المناعة البشري.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستَخدَم لعلاج العدوى الفطرية، مثل: فوريكونازول أو فلوكونازول أو كيتوكونازول أو إتراكونازول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستَخدَم لعلاج الصَّرع، مثل: فينيتوين أو فينوباربيتال أو كَرْبامازِيبين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستَخدَم لعلاج ارتفاع ضغط الدَّم أو مشاكل القلب، مثل: فيراباميل أو نيكارديبين أو ديلتِيازِيم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; درونيدارون، وهو دواء يستخدم للمساعدة على تنظيم ضربات القلب لديك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأْدوية التي تُستَخدَم لخفض مستوى الكوليسترول بالدَّم، مثل: أتورفاستاتين أو برافاستاتين أو الفيبرات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستَخدَم لعلاج النوبات التشنُّجية الحادة، أو التي تُستَخدَم كمُهدئ قبل أو أثناء العمليات الجراحية أو الإجراءات الطبية الأخرى، مثل ميدازولام.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكانابيديول (تشمل إستخدامات أخرى من بينها علاج نوبات الصرع).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوكتريوتيد، وهو دواء يُستَخدَم لعلاج ضخامة الأطراف، وهو اضطراب هرموني نادر يحدث عادةً لدى البالغين في منتصف العمر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيماتينيب، دواء يُستَخدَم لتثبيط نمو الخلايا غير الطبيعية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جونز (<em>هايبريكوم برفوراتام</em>)، دواء عشبي يُستخدم لعلاج الاكتئاب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا احتجت إلى تلقي تطعيم، فتحدَّث إلى طبيبك أولًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;د.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تناوُل عقار سيرتيكان مع الطعام والشراب </strong></p><p dir="RTL">قد يُؤثر وجود الطعام على مدى امتصاص عقار سيرتيكان. للحفاظ على مستويات ثابتة في جسمك، يجب أن تتناول دائمًا عقار سيرتيكان بالطريقة نفسها. يجب أن تتناوله إما مع الطعام دائمًا أو على معدة فارغة دائمًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتناول عقار سيرتيكان مع عصير الجريب فروت أو فاكهة الجريب فروت؛ فقد يؤثران على كيفية عمل عقار سيرتيكان في الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ه.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الحمل والرَّضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">إذا كنتِ حاملًا، فلا تتناولي عقار سيرتيكان ما لم يرَ طبيبكِ ضرورة مُلِحة لتناوُله. إذا كنتِ سيدة ولديكِ القدرة على الحَمْل، فيجب عليكِ استخدام وسيلة فعَّالة لمنع الحمل أثناء العلاج بعقار سيرتيكان ولمدة 8 أسابيع بعد إيقاف العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعتقدين أنكِ قد تكونين حاملًا، فاستشيري طبيبكِ أو الصيدلي قبل تناوُل عقار سيرتيكان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أَلَّا تمارسي الرضاعة الطبيعيَّة أثناء تناوُل عقار سيرتيكان. من غير المعروف ما إذا كان عقار سيرتيكان يمر إلى لبن الأم أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يكون لعقار سيرتيكان تأثير على الخصوبة لدى الذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;و.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تأثير المستحضر على القيادة واستخدام الآلات </strong></p><p dir="RTL">لم يتم إجراء أيَّة دراسات بشأن التأثيرات في القدرة على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ز.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>معلومات هامَّة عن بعض مكونات عقار سيرتيكان&nbsp; </strong></p><p dir="RTL">تحتوي أقراص عقار سيرتيكان على اللاكتوز. إذا كنت لا تتحمل بعض السكريات (الجلوكوز، الجالاكتوز، اللاكتوز)، فيجب أن تتحدَّث إلى طبيبك قبل تناوُل عقار سيرتيكان.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيقرر طبيبك بالضبط الجرعة التي عليك تناوُلها من عقار سيرتيكان والموعد الذي عليك تناوُلها فيه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تناول دائمًا عقار سيرتيكان كما أخبرك طبيبك أو الصيدلي الخاص بك، بالضبط. يُرجى مراجعة الطبيب أو الصيدلي إذا لم تكن متأكدًا من كيفية التَّناوُل.</p><p dir="RTL">&nbsp;</p><p>ما هي الكمية التي يجب أن تتناولها؟</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة البدء المُعتادة هي 1.5 مجم/يوم في حالات زرع الكُلى والقلب و2.0 مجم/ يوم في حالات زرع الكبد.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُقسَّم عادةً إلى جرعتين، واحدة في الصباح والأخرى في المساء.</p><p dir="RTL">&nbsp;</p><p>طريقة تناوُل عقار سيرتيكان</p><p dir="RTL">يجب تناوُل عقار سيرتيكان عن طريق الفم فقط.</p><p dir="RTL">لا تسحق الأقراص.</p><p dir="RTL">ابتلع الأقراص كاملة مع كوب من الماء.</p><p dir="RTL">يجب أن تتناول الجرعة الأولى من هذا الدَّواء مبكرًا قدر الإمكان بعد عملية زراعة الكُلى والقلب وبعد نحو أربعة أسابيع من عملية زراعة الكبد.</p><p dir="RTL">يجب أن تتناول الأقراص بمصاحبة سيكلوسبورين في صورة مُستَحلَب دقيق في حالات زرع الكُلى والقلب، ومع تاكروليموس في حالات زرع الكبد.</p><p dir="RTL">لا تنتقل من العلاج بعقار سيرتيكان أقراص إلى عقار سيرتيكان أقراص قابلة للانتشار دون إخبار طبيبك أولًا.</p><p dir="RTL">&nbsp;</p><p>المراقبة أثناء علاجك بعقار سيرتيكان</p><p dir="RTL">قد يُعدِّل طبيبك جرعتك وفقًا لكمية عقار سيرتيكان الموجودة لديك في الدَّم ووفقًا لمدى استجابتك للعلاج. سيُجري طبيبك اختبارات دم منتظمة لقياس كمية إفيروليموس وسيكلوسبورين لديك في الدَّم. سيُراقِب طبيبك أيضًا وظائف الكُلى لديك بعناية وكمية الدهون والسكر في دمك وكذلك كمية البروتينات في البول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من عقار سيرتيكان </strong></p><p dir="RTL">إذا تناولت كمية من هذا الدَّواء أكثر مما يجب، فتحدَّث إلى طبيبك فورًا.</p><p dir="RTL">&nbsp;</p><p>نسيان تناوُل جرعة من عقار سيرتيكان</p><p dir="RTL">إذا أغفلت تناوُل جرعتك من عقار سيرتيكان، فتناولها بمجرد تذكرك لها ثم تناول الجرعة التَّالية في الوقت المُعتاد. يُرجى استشارة طبيبك. لا تتناول جرعة مضاعفة لتعويض قرص أغفلته.</p><p dir="RTL">&nbsp;</p><p>التوقف عن تناوُل عقار سيرتيكان</p><p dir="RTL">لا تتوقف عن تناوُل الأقراص ما لم يخبرك الطبيب بذلك. ستحتاج إلى تناوُل هذا الدَّواء طالما احتجت إلى كابتات للمناعة؛ لمنع رفض ما تم زرعه لك سواء كان كُلى أو قلبًا أو كبدًا. إذا توقفت عن تناوُل عقار سيرتيكان، فستكون عُرضة لخطر أكبر يتمثل في رفض جسمك للعضو المزروع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء أعراضًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لأنك تتناول عقار سيرتيكان بمصاحبة أدوية أخرى، فلا يكون من الواضح دائمًا ما إذا كانت الأعراض الجانبية ناجمة عن تناوُل عقار سيرتيكان أم عن الأدوية الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية التَّالية تحتاج إلى العناية الطبية الفورية: </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئتين،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمى وكدمات أسفل الجلد قد تبدو في هيئة نقاط حمراء، مع أو بدون تعب غير مُبَرر، ارتباك/التباس، اصفرار الجلد أو العينين، انخفاض كمية البول عند التبوُّل (اعتلال الأوعية الدَّقيقة الخثاري، مُتلازِمة انحلال الدَّم اليوريمي).<strong> </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أُصِبت بأي مما يلي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض مستمرة أو متفاقمة بالرئة/ التَّنفس مثل: السُّعال، أو صعوبة في التَّنفس أو أزيز بالصدر،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمى، شعور عام بالإعياء، ألم بالصدر أو البطن، قشعريرة، إحساس بالحُرقة عند التبوُّل،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم الوجه أو الشفتين أو اللسان أو الحَلْق،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة البلع،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كدمات تلقائية أو نزيف بدون سبب واضح،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم، شعور غير مُعتاد بالدفء، تورُّم أو ارتشاح من موضع الجراحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تتوقف عن تناوُل عقار سيرتيكان <strong>وتخبر طبيبك فورًا</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الأخرى التي تم الإبلاغ عنها تشمل الآتي: </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًّا </strong><em>(قد تُؤثر على أكثر من 1 من بين كل 10&nbsp;مرضى) </em></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى (الفيروسية والبكتيرية والفطرية)،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التَّنفسي السفلي، مثل عدوى الرئة، بما في ذلك الالتهاب الرئوي،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التَّنفسي العلوي، مثل التهاب البلعوم، ونزلة البرد،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى المسالك البولية،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدَّم (انخفاض عدد خلايا الدَّم الحمراء)،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات خلايا الدَّم البيضاء؛ مما يُؤدي إلى وجود خطورة أكبر للإصابة بعدوى، انخفاض تعداد الصَّفائح الدَّموية، الأمر الذي قد يُؤدي إلى نزيف و/أو كدمات أسفل الجلد،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى الدهون (الشحوم والكوليسترول والدهون الثلاثية) في الدَّم،&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور مرض السُّكَّري (ارتفاع مستوى السُّكَّر في الدَّم)،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى البوتاسيوم في الدَّم،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الخلود إلى النوم (أرق)،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجمُّع السوائل في الكيس المحيط بالقلب، وفي الحالات الشَّديدة، يُمكِن أن يقلل من قدرة القلب على ضخ الدَّم،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدَّم،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخثُّر وريدي (انسداد أحد الأوردة الرئيسية بفعل جلطة دموية)،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجمُّع السوائل على الرئتين وفي تجويف الصدر، وهو الأمر الذي قد يُصيبك بصعوبة التَّنفس في الحالات الشديدة،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سُعال،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التَّنَفُّس،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إِسْهال،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء (غثيان)،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بالإعياء (قيء)،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم عام،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمى،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تراكم السوائل في الأنسجة،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التئام الجروح بصورة غير طبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong> <em>(قد تُؤثر على ما يصل إلى مريض واحد من كل ١٠&nbsp;مرضى)</em></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسمم دموي،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بالجروح،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السرطانات والأورام الحميدة،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الجلد،</p><p dir="RTL">تلف الكُلى مع انخفاض تعداد الصفائح الدَّموية وخلايا الدَّم الحمراء، مع أو بدون طفح جلدي (فرفرية نقص الصَّفائح الدَّموية/مُتلازِمة انحلال الدَّم اليوريمي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكسير خلايا الدَّم الحمراء،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات خلايا الدَّم الحمراء والصفائح الدَّموية،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات القلب السريعة،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد خلايا الدَّم (قد تشمل الأعراض ضعفًا وكدمات وعدوى متكررة)،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات في الأوعية الدَّموية بالكُلى، الأمر الذي قد يُؤدي إلى فقدان العضو المزروع في الغالب خلال 30 يومًا بعد زرع الكُلى،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات نزفية،&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكوُّن كيس يحتوي على سائل لمفاوي،&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الفم أو الحَلْق،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرُّحات بالفم،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حب الشباب،&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرى (ارتكاريا) وأعراض حساسية أخرى، مثل: تورُّم الوجه أو الحَلْق (وذمة وعائية)،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمفاصل،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالعضلات،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود البروتين في البول،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الكُلى،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عَنانَة (اضطرابات الانتصاب)،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فتق في موضع الجراحة،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية في اختبارات الكبد،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الدَّورة الشهرية (بما في ذلك غيابها أو التعرُّض لدورات حيض غزيرة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong><em> (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ١٠٠ مريض)</em>:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان النسيج اللمفاوي (سرطان الغدد اللمفاوية/ اضطراب لمفاوي تكاثري بعد الزرع)،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات التستوستيرون،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئتين،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يرقان،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكيُّسات المبيض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية أخرى<em>:</em></strong></p><p dir="RTL">قد حدثت أعراض جانبية أخرى في عدد ضئيل جدًّا من الأشخاص إِلَّا أنَّ معدل تكرارها الدقيق غير معروف:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تراكُم غير طبيعي للبروتينات في الرئتين (قد تشمل الأعراض سُعالًا جافًّا مستمرًّا، وإرهاقًا وصعوبة في التَّنفس)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم، شعور بالثقل أو الضيق، ألم، تحريك أجزاء من الجسم على نحو محدود (قد يحدث هذا في أي جزء من أجزاء الجسم وهو علامة مُحتملة على تراكم السوائل بشكل غير طبيعي في الأنسجة الرَّخوة بسبب انسداد في الجهاز اللمفاوي، يُعرف أيضًا بالوذمة اللمفيَّة)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي شديد مع تورُّم الجلد،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الحديد في الدَّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك مخاوف بشأن أي من هذه الأعراض، <strong>فأخبر طبيبك</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يكون هناك أيضًا أعراض جانبية لست على علم بها، مثل وجود نتائج غير طبيعية في الاختبارات المعملية، بما في ذلك اختبارات وظائف الكُلى. هذا يعني أن طبيبك سيُجري اختبارات الدَّم لمراقبة أي تغيُّرات في الكُلى لديك أثناء علاجك بعقار سيرتيكان.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ عقار سيرتيكان بعيدًا عن رؤية ومتناول الأطفال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يخزن في درجة حرارة تتعدى 30 درجة مئوية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل عقار سيرتيكان بعد انتهاء تاريخ الصلاحية المدون على العبوة الكرتونية بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُخزن الشرائط داخل العبوة الكرتونية الأصلية للحماية من الضوء والرطوبة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم أي عبوة لعقار سيرتيكان تكون تالفة أو يبدو عليها علامات العبث.</p><p dir="RTL">&bull;&nbsp; لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعَّالة هي إفيروليموس. يحتوي كل قرص على 0.25 أو 0.5 أو 0.75 مجم إفيروليموس.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار سيرتيكان 0.25 مجم أقراص: بوتيل هيدروكسي تولوين (E321)، ستيرات الماغنسيوم، لاكتوز أحادي الهيدرات (2 مجم)، هيبروميلوز، كروسبوفيدون ولاكتوز لا مائي (51 مجم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار سيرتيكان 0.5 مجم أقراص: بوتيل هيدروكسي تولوين (E321)، ستيرات الماغنسيوم، لاكتوز أحادي الهيدرات (4 مجم)، هيبروميلوز، كروسبوفيدون ولاكتوز لا مائي (74 مجم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار سيرتيكان 0.75 مجم أقراص: بوتيل هيدروكسي تولوين (E321)، ستيرات الماغنسيوم، لاكتوز أحادي الهيدرات (7 مجم)، هيبروميلوز، كروسبوفيدون ولاكتوز لا مائي (112 مجم).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عقار سيرتيكان 0.25 مجم أقراص هو عبارة عن أقراص ذات لون أبيض مائل إلى الأصفر، رخاميَّة الشكل، دائرية، مسطحة، قطرها 6 مللي مترات، ومحفور على أحد وجهيها &quot;C&quot; وعلى الوجه الآخر &quot;NVR&quot;.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار سيرتيكان 0.5 مجم أقراص هو عبارة عن أقراص ذات لون أبيض مائل إلى الأصفر، رخاميَّة الشكل، دائرية، مسطحة، قطرها 7 مللي مترات، ومحفور على أحد وجهيها &quot;CH&quot; وعلى الوجه الآخر &quot;NVR&quot;.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار سيرتيكان 0.75 مجم أقراص هو عبارة عن أقراص ذات لون أبيض مائل إلى الأصفر، رخاميَّة الشكل، دائرية، مسطحة، قطرها 8.5 مللي مترات، ومحفور على أحد وجهيها &quot;CL&quot; وعلى الوجه الآخر &quot;NVR&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر عقار سيرتيكان أقراص في عبوات تحتوي على 60 قرصًا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك حق التَّسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.<br />www.Novartis.com&nbsp;<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ‌د.	تم آخر اعتماد لهذه النَّشرة في 6/2022 من قِبَل  المملكة المتحدة
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Certican® 0.25 mg tablets
Certican® 0.5 mg tablets 
Certican® 0.75 mg tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 0.25 mg, 0.5 mg, 0.75 mg everolimus. 

Excipient(s) with known effect: 

-	For Certican® 0.25 mg: Each tablet contains 2 mg lactose monohydrate and 51 mg Anhydrous lactose. For the full list of excipients, see section 6.1.
-	For Certican® 0.5 mg: Each tablet contains 4 mg lactose monohydrate and 74 mg Anhydrous lactose. For the full list of excipients, see section 6.1.
-	For Certican® 0.75 mg: Each tablet contains 7 mg lactose monohydrate and 112 mg Anhydrous lactose. For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet
Tablets are white to yellowish, marbled, round, flat with a bevelled edge.
0.25 mg (diameter of 6 mm): engraved with “C” on one side and “NVR” on the other.
0.5 mg (diameter of 7 mm): engraved with “CH” on one side and “NVR” on the other. 
0.75 mg (diameter of 8.5 mm): engraved with “CL” on one side and “NVR” on the other.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Kidney and heart transplantation</u></p><p>Certican is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk<strong><em> </em></strong>receiving an allogeneic renal or cardiac transplant. In kidney and heart transplantation, Certican should be used in combination with ciclosporin for microemulsion and corticosteroids.</p><p>&nbsp;</p><p><u>Liver transplantation</u></p><p>Certican is indicated for the prophylaxis of organ rejection in adult patients receiving a hepatic transplant. In liver transplantation, Certican should be used in combination with tacrolimus and corticosteroids.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Certican should only be initiated and maintained by physicians who are experienced in immunosuppressive therapy following organ transplantation and who have access to everolimus whole blood concentration monitoring.</p><p>&nbsp;</p><p><u>Posology</u></p><p><em><u>Adults</u></em></p><p>An initial dose regimen of 0.75&nbsp;mg twice daily in co-administration with ciclosporin is recommended for the general kidney and heart transplant population, administered as soon as possible after transplantation.</p><p>The dose of 1.0 mg twice daily in co-administration with tacrolimus is recommended for the hepatic transplant population with the initial dose approximately 4&nbsp;weeks after transplantation.</p><p>&nbsp;</p><p>Patients receiving Certican may require dose adjustments based on blood concentrations achieved, tolerability, individual response, change in co-medications and the clinical situation. Dose adjustments can be made at 4-5&nbsp;day intervals (see <em>Therapeutic drug monitoring</em>)<em>.</em></p><p><em>&nbsp;</em></p><p><em><u>Special population</u></em></p><p><em>Black patients</em></p><p>The incidence of biopsy-proven acute rejection episodes was significantly higher in black renal transplant patients compared with non-black patients. There is limited information indicating that black patients may require a higher Certican dose to achieve similar efficacy to non-black patients (see section 5.2). Currently, the efficacy and safety data are too limited to allow specific recommendations for use of everolimus in black patients.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>In paediatric renal and hepatic transplant patients, Certican should not be used. The safety and efficacy of Certican in paediatric cardiac transplant patients has not been established (see section 5.1).</p><p>&nbsp;</p><p><em>Elderly patients (&ge;65&nbsp;years)</em></p><p>Clinical experience in patients &gt;65&nbsp;years of age is limited. Although data are limited, there are no apparent differences in the pharmacokinetics of everolimus in patients <strong>&ge;</strong>65-70&nbsp;years of age (see section 5.2).</p><p>&nbsp;</p><p><em>Patients with renal impairment</em></p><p>No dosage adjustment is required (see section 5.2).</p><p>&nbsp;</p><p><em>Patients with impaired hepatic function</em></p><p>Everolimus whole blood trough concentrations should be closely monitored in patients with impaired hepatic function. The dose should be reduced to approximately two thirds of the normal dose for patients with mild hepatic impairment (Child-Pugh Class A), to approximately one half of the normal dose for patients with moderate hepatic impairment (Child Pugh Class B), and to approximately one third of the normal dose for patients with severe hepatic impairment (Child Pugh Class C). Further dose titration should be based on therapeutic drug monitoring (see section 5.2). Reduced doses rounded to the nearest tablet strength are tabulated below:</p><p>&nbsp;</p><p><strong>Table&nbsp;1 Certican dose reduction in patients with hepatic impairment</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Normal hepatic function</strong></p></td><td style="vertical-align:top"><p><strong>Mild hepatic impairment (Child-Pugh A)</strong></p></td><td style="vertical-align:top"><p><strong>Moderate hepatic impairment (Child-Pugh B)</strong></p></td><td style="vertical-align:top"><p><strong>Severe hepatic impairment (Child-Pugh C)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and cardiac transplantation</strong></p></td><td style="vertical-align:top"><p>0.75&nbsp;mg <em>b.i.d.</em></p></td><td style="vertical-align:top"><p>0.5&nbsp;mg <em>b.i.d.</em></p></td><td style="vertical-align:top"><p>0.5&nbsp;mg <em>b.i.d.</em></p></td><td style="vertical-align:top"><p>0.25&nbsp;mg <em>b.i.d.</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatic transplantation</strong></p></td><td style="vertical-align:top"><p>1&nbsp;mg <em>b.i.d.</em></p></td><td style="vertical-align:top"><p>0.75&nbsp;mg <em>b.i.d.</em></p></td><td style="vertical-align:top"><p>0.5&nbsp;mg <em>b.i.d.</em></p></td><td style="vertical-align:top"><p>0.5&nbsp;mg <em>b.i.d.</em></p></td></tr></tbody></table><p><em><u>&nbsp;</u></em></p><p><u>Therapeutic drug monitoring</u></p><p>The use of drug assays with adequate performance characteristics when targeting low concentrations of ciclosporin or tacrolimus is recommended.</p><p>&nbsp;</p><p>Certican has a narrow therapeutic index which may require adjustments in dosing to maintain therapeutic response. Routine everolimus whole blood therapeutic drug concentration monitoring is recommended. Based on exposure-efficacy and exposure-safety analysis, patients achieving everolimus whole blood trough concentrations &sup3;3.0&nbsp;ng/ml have been found to have a lower incidence of biopsy-proven acute rejection in renal, cardiac and hepatic transplantation compared with patients whose trough concentrations are below 3.0&nbsp;ng/ml. The recommended upper limit of the therapeutic range is 8&nbsp;ng/ml. Exposure above 12&nbsp;ng/ml has not been studied. These recommended ranges for everolimus are based on chromatographic methods.</p><p>&nbsp;</p><p>It is especially important to monitor everolimus blood concentrations in patients with hepatic impairment during concomitant administration of strong CYP3A4 inducers and inhibitors, when switching formulation, and/or if ciclosporin dosing is markedly reduced (see section 4.5). Everolimus concentrations might be slightly lower following dispersible tablet administration.</p><p>&nbsp;</p><p>Ideally, dose adjustments of Certican should be based on trough concentrations obtained &gt;4-5&nbsp;days after the previous dosing change. There is an interaction between ciclosporin and everolimus, and everolimus concentrations may therefore decrease if ciclosporin exposure is markedly reduced (i.e. trough concentration &lt;50&nbsp;ng/ml).</p><p>&nbsp;</p><p>Patients with hepatic impairment should preferably have trough concentrations in the upper part of the 3-8&nbsp;ng/ml exposure range.</p><p>&nbsp;</p><p>After starting treatment or after a dose adjustment, monitoring should be performed every 4 to 5&nbsp;days until 2&nbsp;consecutive trough concentrations show stable everolimus concentrations, as the prolonged half-lives in hepatically impaired patients delay the time to reach steady state (see sections 4.4 and 5.2). Dose adjustments should be based on stable everolimus trough concentrations.</p><p>&nbsp;</p><p><u>Ciclosporin dose recommendation in renal transplantation</u></p><p>Certican should not be used long-term together with full doses of ciclosporin. Reduced exposure to ciclosporin in Certican-treated renal transplant patients improves renal function. Based on experience gained from study A2309, ciclosporin exposure reduction should be started immediately after transplantation with the following recommended whole blood trough concentration windows:</p><p>&nbsp;</p><p><strong>Table&nbsp;2 Renal transplantation: recommended target ciclosporin blood trough concentration windows</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:613px"><tbody><tr><td style="vertical-align:top"><p><strong>Target ciclosporin C<sub>0 </sub>(ng/m</strong><strong>l</strong><strong>)</strong></p></td><td style="vertical-align:top"><p><strong>Month&nbsp;1</strong></p></td><td style="vertical-align:top"><p><strong>Months&nbsp;2-3</strong></p></td><td style="vertical-align:top"><p><strong>Months&nbsp;4-5</strong></p></td><td style="vertical-align:top"><p><strong>Months&nbsp;6-12</strong></p></td></tr><tr><td style="vertical-align:top"><p>Certican groups</p></td><td style="vertical-align:top"><p>100-200</p></td><td style="vertical-align:top"><p>75-150</p></td><td style="vertical-align:top"><p>50-100</p></td><td style="vertical-align:top"><p>25-50</p></td></tr></tbody></table><p>&nbsp;</p><p>(Measured C<sub>0</sub> and C2 concentrations are shown in section 5.1).</p><p>&nbsp;</p><p>Prior to dose reduction of ciclosporin it should be ascertained that steady-state everolimus whole blood trough concentrations are equal to or above 3&nbsp;ng/ml.</p><p>&nbsp;</p><p>There are limited data regarding dosing Certican with ciclosporin trough concentrations below 50&nbsp;ng/ml, or C2 concentrations below 350&nbsp;ng/ml, in the maintenance phase. If the patient cannot tolerate reduction of ciclosporin exposure, the continued use of Certican should be reconsidered.</p><p><u>&nbsp;</u></p><p><u>Ciclosporin dose recommendation in cardiac transplantation</u></p><p>Cardiac transplant patients in the maintenance phase should have their ciclosporin dose reduced as tolerated in order to improve kidney function. If impairment of renal function is progressive or if the calculated creatinine clearance is &lt;60&nbsp;ml/min, the treatment regimen should be adjusted. In cardiac transplant patients, the ciclosporin dose may be based on ciclosporin blood trough concentrations. See section 5.1 for experience with reduced ciclosporin blood concentrations.</p><p>&nbsp;</p><p>In cardiac transplantation, there are limited data regarding dosing Certican with ciclosporin trough concentrations of 50-100&nbsp;ng/ml after 12&nbsp;months.</p><p>&nbsp;</p><p>Prior to dose reduction of ciclosporin it should be ascertained that steady-state everolimus whole blood trough concentrations are equal to or above 3&nbsp;ng/ml<em>.</em></p><p>&nbsp;</p><p><u>Tacrolimus dose recommendation in hepatic transplantation</u></p><p>Hepatic transplant patients should have their tacrolimus exposure reduced to minimise calcineurin-related renal toxicity. The tacrolimus dose should be reduced starting approximately 3&nbsp;weeks after initiating co-administration with Certican, based on targeted tacrolimus blood trough concentrations (C<sub>0</sub>) of 3-5&nbsp;ng/ml. In a controlled clinical trial, complete withdrawal of tacrolimus has been associated with an increased risk of acute rejections.</p><p>&nbsp;</p><p>Certican has not been evaluated with full-dose tacrolimus in controlled clinical trials.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Certican is for oral use only.</p><p>&nbsp;</p><p>The daily dose of Certican should always be given orally in two divided doses consistently either with or without food (see section 5.2) and at the same time as ciclosporin for microemulsion or tacrolimus (see <em>Therapeutic drug monitoring</em>)<em>.</em></p><p>&nbsp;</p><p>Certican tablets should be swallowed whole with a glass of water and not crushed before use. For patients unable to swallow whole tablets, Certican dispersible tablets are also available (see Certican dispersible tablets Summary of Product Characteristics).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Certican is contraindicated in patients with a known hypersensitivity to everolimus, sirolimus, or to any of the excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Management of immunosuppression</u></p><p>In clinical trials, Certican has been administered concurrently with ciclosporin for microemulsion, basiliximab, or with tacrolimus, and corticosteroids. Certican in combination with immunosuppressive agents other than these has not been adequately investigated.</p><p>&nbsp;</p><p>Certican has not been adequately studied in patients at high immunological risk.</p><p>&nbsp;</p><p><u>Combination with thymoglobulin induction</u></p><p>Strict caution is advised with the use of thymoglobulin (rabbit anti-thymocyte globulin) induction and the Certican/ciclosporin/steroid regimen. In a clinical study in heart transplant recipients (Study A2310, see section 5.1), an increased incidence of serious infections including fatal infections was observed within the first three months after transplantation in the subgroup of patients who had received induction with rabbit anti-thymocyte globulin<strong>.</strong></p><p><u>&nbsp;</u></p><p><u>Serious and opportunistic infections</u></p><p>Patients treated with immunosuppressants, including Certican, are at increased risk for opportunistic infections (bacterial, fungal, viral and protozoal). Among these conditions are BK virus-associated nephropathy and JC virus-associated progressive multiple leukoencephalopathy (PML). These infections are often related to a high total immunosuppressive burden and may lead to serious or fatal conditions that physicians should consider in the differential diagnosis in immunosuppressed patients with deteriorating renal function or neurological symptoms. Fatal infections and sepsis have been reported in patients treated with Certican (see section 4.8).</p><p>&nbsp;</p><p>In clinical trials with Certican, antimicrobial prophylaxis for <em>Pneumocystis jiroveci (carinii)</em> pneumonia and Cytomegalovirus (CMV) was recommended following transplantation, particularly for patients at increased risk for opportunistic infections.</p><p>&nbsp;</p><p><u>Liver function impairment</u></p><p>Close monitoring of everolimus whole blood trough concentrations (C<sub>0</sub>) and everolimus dose adjustment is recommended in patients with impaired hepatic function (see section 4.2).</p><p>&nbsp;</p><p>Because of longer everolimus half-lives in patients with hepatic impairment (see section 5.2), everolimus therapeutic monitoring after starting treatment or after a dose adjustment should be performed until stable concentrations are reached.</p><p>&nbsp;</p><p><u>Interaction with oral CYP3A4 substrates</u></p><p>Caution should be exercised when Certican is taken in combination with orally administered CYP3A4 substrates with a narrow therapeutic index due to the potential for drug interactions. If Certican is taken with orally administered CYP3A4 substrates with a narrow therapeutic index (e.g. pimozide, terfenadine, astemizole, cisapride, quinidine or ergot alkaloid derivatives), the patient should be monitored for undesirable effects described in the product information of the orally administered CYP3A4 substrate (see section 4.5).</p><p>&nbsp;</p><p><u>Interaction with strong inhibitors or inducers of CYP3A4 and/or P-glycoprotein (PgP)</u></p><p>Co-administration with strong inhibitors of CYP3A4 and/or the multidrug efflux pump P&shy;glycoprotein (PgP) (e.g. ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir) may increase everolimus blood levels and is not recommended unless the benefit outweighs the risk.</p><p>Coadministration with strong inducers of CYP3A4 and/or PgP (e.g. rifampicin, rifabutin, carbamazepine, phenytoin) is not recommended unless the benefit outweighs the risk. If coadministration of inducers or inhibitors of CYP3A4 and/or PgP cannot be avoided, it is recommended that everolimus whole blood trough concentrations and the clinical condition of the patient be monitored while they are concurrently administered with everolimus and after their discontinuation. Dose adjustments of everolimus may be required (see section 4.5).</p><p>&nbsp;</p><p><u>Lymphomas and other malignancies</u></p><p>Patients receiving a regimen of immunosuppressive medicinal products, including Certican, are at increased risk of developing lymphomas or other malignancies, particularly of the skin (see section 4.8). The absolute risk seems related to the duration and intensity of immunosuppression rather than to the use of a specific medicinal product. Patients should be monitored regularly for skin neoplasms and advised to minimise exposure to UV light and sunlight, and to use appropriate sunscreen.</p><p>&nbsp;</p><p><u>Hyperlipidaemia</u></p><p>The use of Certican with ciclosporin for microemulsion or tacrolimus in transplant patients has been associated with increased serum cholesterol and triglycerides that may require treatment. Patients receiving Certican should be monitored for hyperlipidaemia and, if necessary, treated with lipid-lowering medicinal products and have appropriate dietary adjustments made (see section 4.5). The risk/benefit should be considered in patients with established hyperlipidaemia before initiating an immunosuppressive regimen including Certican. Similarly, the risk/benefit of continued Certican therapy should be re-evaluated in patients with severe refractory hyperlipidaemia. Patients administered a HMG-CoA reductase inhibitor and/or fibrate should be monitored for the possible development of rhabdomyolysis and other adverse effects as described in the Summary of Product Characteristics for the medicinal product(s) concerned (see section 4.5).</p><p>&nbsp;</p><p><u>Angioedema</u></p><p>Certican has been associated with the development of angioedema. In the majority of cases reported, patients were receiving ACE inhibitors as co-medication.</p><p>&nbsp;</p><p><u>Everolimus and calcineurin inhibitor-induced renal dysfunction</u></p><p>In renal and cardiac transplantation, Certican with full-dose ciclosporin increases the risk of renal dysfunction. Reduced doses of ciclosporin are required for use in combination with Certican in order to avoid renal dysfunction. Appropriate adjustment of the immunosuppressive regimen, in particular reduction of the ciclosporin dose, should be considered in patients with elevated serum creatinine levels.</p><p>&nbsp;</p><p>In a liver transplant study, Certican with reduced tacrolimus exposure has not been found to worsen renal function in comparison to standard exposure tacrolimus without Certican. Regular monitoring of renal function is recommended in all patients. Caution should be exercised when co-administering other medicinal products that are known to have a negative effect on renal function.</p><p>&nbsp;</p><p><u>Proteinuria</u></p><p>The use of Certican with calcineurin inhibitors in transplant recipients has been associated with increased proteinuria. The risk increases with higher everolimus blood concentrations. In renal transplant patients with mild proteinuria while on maintenance immunosuppressive therapy including a calcineurin inhibitor (CNI), there have been reports of worsening proteinuria when the CNI is replaced by Certican. Reversibility has been observed with interruption of Certican and reintroduction of the CNI. The safety and efficacy of switching from a CNI to Certican in such patients have not been established. Patients receiving Certican should be monitored for proteinuria.</p><p>&nbsp;</p><p><u>Renal graft thrombosis</u></p><p>An increased risk of kidney arterial and venous thrombosis, resulting in graft loss, has been reported, mostly within the first 30 days post-transplantation.</p><p>&nbsp;</p><p><u>Wound-healing complications</u></p><p>Certican, like other mTOR inhibitors, can impair healing, increasing the occurrence of post-transplant complications such as wound dehiscence, fluid accumulation and wound infection, which may require further surgical attention. Lymphocele is the most frequently reported such event in renal transplant recipients and tends to be more frequent in patients with a higher body mass index. The frequency of pericardial and pleural effusion is increased in cardiac transplant recipients and the frequency of incisional hernias is increased in liver transplant recipients.</p><p>&nbsp;</p><p><u>Thrombotic microangiopathy/Thrombotic thrombocytopenic purpura/Haemolytic uraemic syndrome</u></p><p>The concomitant administration of Certican with a calcineurin inhibitor (CNI) may increase the risk of CNI-induced haemolytic uraemic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy.</p><p>&nbsp;</p><p><u>Vaccinations</u></p><p>Immunosuppressants may affect the response to vaccination. During treatment with immunosuppressants, including everolimus, vaccination may be less effective. The use of live vaccines should be avoided.</p><p>&nbsp;</p><p><u>Interstitial lung disease/non-infectious pneumonitis</u></p><p>A diagnosis of interstitial lung disease (ILD) should be considered in patients presenting with symptoms consistent with infectious pneumonia but not responding to antibiotic therapy and in whom infectious, neoplastic and other non-drug causes have been ruled out through appropriate investigations. Cases of ILD have been reported with Certican, which generally resolve on drug interruption with or without glucocorticoid therapy. However, fatal cases have also occurred (see section 4.8).</p><p>&nbsp;</p><p><u>New onset diabetes mellitus</u></p><p>Certican has been shown to increase the risk of new onset diabetes mellitus after transplantation. Blood glucose concentrations should be monitored closely in patients treated with Certican.</p><p>&nbsp;</p><p><u>Male infertility</u></p><p>There are literature reports of reversible azoospermia and oligospermia in patients treated with mTOR inhibitors. As preclinical toxicology studies have shown that everolimus can reduce spermatogenesis, male infertility must be considered a potential risk of prolonged Certican therapy.</p><p>&nbsp;</p><p><u>Risk of intolerance of excipients</u></p><p>Certican tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Everolimus is mainly metabolised by CYP3A4 in the liver and to some extent in the intestinal wall and is a substrate for the multidrug efflux pump, P-glycoprotein (PgP). Therefore, absorption and subsequent elimination of systemically absorbed everolimus may be influenced by medicinal products that affect CYP3A4 and/or P-glycoprotein. Concurrent treatment with strong 3A4 inhibitors and inducers is not recommended. Inhibitors of P-glycoprotein may decrease the efflux of everolimus from intestinal cells and increase everolimus blood concentrations. <em>In vitro</em>, everolimus was a competitive inhibitor of CYP3A4 and a mixed inhibitor of CYP2D6. All <em>in vivo</em> interaction studies were conducted without concomitant ciclosporin.</p><p>&nbsp;</p><p><strong>Table 3 Effects of other active substances on everolimus</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:637px"><tbody><tr><td style="vertical-align:top"><p><strong>A</strong><strong>ctive substance by interaction</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Interaction &ndash; Change in Everolimus AUC/Cmax Geometric mean ratio (observed range)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>R</strong><strong>ecommendations concerning co- administration</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong><em>Strong </em></strong><strong>C</strong><strong>Y</strong><strong>P</strong><strong>3A4/PgP inhibitors</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>K</strong><strong>etoconazole</strong></p></td><td colspan="2" style="vertical-align:top"><p>AUC &uarr;15.3-fold (range 11.2-22.5) Cmax &uarr;4.1-fold (range 2.6-7.0)</p></td><td colspan="2" rowspan="5" style="vertical-align:top"><p>Co-administration with strong CYP3A4/PgP-inhibitors is not recommended unless the benefit outweighs the risk.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Itraconazole, posaconazole, voriconazole</strong></p></td><td colspan="2" rowspan="4" style="vertical-align:top"><p>Not studied. Large increase in everolimus concentration is expected.</p></td></tr><tr><td style="vertical-align:top"><p><strong>T</strong><strong>elithromycin, clarithromycin</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Nefazodone</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Ritonavir, atazanavir, saquinavir, darunavir, indinavir, nelfinavir</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong><em>Moderate </em></strong><strong>C</strong><strong>Y</strong><strong>P</strong><strong>3A4/PgP inhibitors</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>E</strong><strong>rythromycin</strong></p></td><td colspan="2" style="vertical-align:top"><p>AUC &uarr;4.4-fold (range 2.0-12.6) Cmax &uarr;2.0-fold (range 0.9-3.5)</p></td><td rowspan="9" style="vertical-align:top"><p>Everolimus whole blood trough concentrations should be monitored whenever inhibitors of CYP3A4/PgP are concurrently administered and after their discontinuation.</p><p>&nbsp;</p><p>Use caution when co-administration of moderate CYP3A4 inhibitors or PgP inhibitors cannot be avoided.</p><p>Closely monitor for side effects and adjust the everolimus dose as needed (see sections 4.2 and 4.4).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Imatinib</strong></p></td><td colspan="2" style="vertical-align:top"><p>AUC &uarr;3.7-fold&nbsp; Cmax &uarr;2.2-fold</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>V</strong><strong>erapamil</strong></p></td><td colspan="2" style="vertical-align:top"><p>AUC &uarr;3.5-fold (range 2.2-6.3) Cmax &uarr;2.3-fold (range1.3-3.8)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>C</strong><strong>i</strong><strong>closporin oral</strong></p></td><td colspan="2" style="vertical-align:top"><p>AUC &uarr;2.7-fold (range 1.5-4.7) Cmax &uarr;1.8-fold (range 1.3-2.6)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cannabidiol (P-gp inhibitor)</strong></p></td><td colspan="2" style="vertical-align:top"><p>AUC &uarr; 2.5-fold Cmax &uarr; 2.5-fold</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>F</strong><strong>l</strong><strong>uconazole</strong></p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>Not studied. Increased exposure expected.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>D</strong><strong>ilti</strong><strong>azem,</strong></p><p><strong>nicardipine</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Dronedarone</strong></p></td><td colspan="2" style="vertical-align:top"><p>Not studied. Increased exposure expected.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>A</strong><strong>m</strong><strong>prenavir, </strong></p><p><strong>fosamprenavir</strong></p></td><td colspan="2" style="vertical-align:top"><p>Not studied. Increased exposure expected.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>G</strong><strong>rapefruit juice or other food affecting CYP3A4/PgP</strong></p></td><td colspan="2" style="vertical-align:top"><p>Not studied. Increased exposure expected (the effect varies widely).</p></td><td style="vertical-align:top"><p>Combination should be avoided.</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Strong and moderate CYP3A4 inducers</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>R</strong><strong>i</strong><strong>f</strong><strong>ampicin</strong></p></td><td colspan="2" style="vertical-align:top"><p>AUC &darr;63% (range 0-80%) Cmax &darr;58% (range 10-70%)</p></td><td rowspan="4" style="vertical-align:top"><p>Co-administration with strong CYP3A4-inducers is not recommended unless the benefit outweighs the risk.</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Rifabutin</strong></p></td><td colspan="2" style="vertical-align:top"><p>Not studied. Decreased exposure expected.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>C</strong><strong>arbamazepine</strong></p></td><td colspan="2" style="vertical-align:top"><p>Not studied. Decreased exposure expected.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Phenytoin</strong></p></td><td colspan="2" style="vertical-align:top"><p>Not studied. Decreased exposure expected.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Phenobarbital</strong></p></td><td colspan="2" style="vertical-align:top"><p>Not studied. Decreased exposure expected.</p></td><td rowspan="2" style="vertical-align:top"><p>Everolimus whole blood trough concentrations should be monitored whenever inducers of CYP3A4 are concurrently administered and after their discontinuation.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>E</strong><strong>f</strong><strong>avirenz, nevirapine</strong></p></td><td colspan="2" style="vertical-align:top"><p>Not studied. Decreased exposure expected.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>St John&rsquo;s Wort</strong></p><p><strong>(<em>H</em></strong><strong><em>ypericum perforatum</em></strong><strong>)</strong></p></td><td colspan="2" style="vertical-align:top"><p>Not studied. Large decrease in exposure expected.</p></td><td style="vertical-align:top"><p>Preparations containing St John&rsquo;s Wort should not be used during treatment with everolimus</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><strong><u>Agents whose plasma concentrations may be altered by everolimus:</u></strong></p><p>&nbsp;</p><p><u>Octreotide</u></p><p>Co-administration of everolimus (10&nbsp;mg daily) with depot octreotide increased octreotide C<sub>min</sub> with a geometric mean ratio (everolimus/placebo) of 1.47-fold.</p><p>&nbsp;</p><p><u>Ciclosporin </u></p><p>Certican had a minor clinical influence on ciclosporin pharmacokinetics in renal and heart transplant patients receiving ciclosporin for microemulsion.</p><p>&nbsp;</p><p><u>Atorvastatin (CYP3A4 substrate) and pravastatin (PgP substrate)</u></p><p>Single-dose administration of Certican with either atorvastatin or pravastatin to healthy subjects did not influence the pharmacokinetics of atorvastatin, pravastatin and everolimus, as well as total HMG-CoA reductase bioreactivity in plasma to a clinically relevant extent. However, these results cannot be extrapolated to other HMG-CoA reductase inhibitors. Patients should be monitored for the development of rhabdomyolysis and other adverse events as described in the Summary of Product Characteristics of HMG-CoA reductase inhibitors.</p><p>&nbsp;</p><p><u>Oral CYP3A4A substrates</u></p><p>Based on in vitro results, the systemic concentrations obtained after oral daily doses of 10 mg make inhibition of PgP, CYP3A4 and CYP2D6 unlikely. However, inhibition of CYP3A4 and PgP in the gut cannot be excluded. An interaction study in healthy subjects demonstrated that co-administration of an oral dose of midazolam, a sensitive CYP3A4 substrate probe, with everolimus resulted in a 25% increase in midazolam C<sub>max</sub> and a 30% increase in midazolam AUC. The effect is likely to be due to inhibition of intestinal CYP3A4 by everolimus. Hence, everolimus may affect the bioavailability of orally co-administered CYP3A4 substrates. However, a clinically relevant effect on the exposure of systemically administered CYP3A4 substrates is not expected. If everolimus is taken with orally administered CYP3A4 substrates with a narrow therapeutic index (e.g. pimozide, terfenadine, astemizole, cisapride, quinidine or ergot alkaloid derivatives), the patient should be monitored for undesirable effects described in the product information of the orally administered CYP3A4 substrate.</p><p>&nbsp;</p><p><u>Vaccinations</u></p><p>Immunosuppressants may affect the response to vaccination and vaccination during treatment with Certican may be less effective. The use of live vaccines should be avoided.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate data from the use of Certican in pregnant women. Studies in animals have shown reproductive toxicity effects including embryo/foetotoxicity (see section 5.3). The potential risk for humans is unknown. Certican should not be given to pregnant women unless the potential benefit outweighs the potential risk for the foetus. Women of childbearing potential should be advised to use effective contraception methods while they are receiving Certican and up to 8&nbsp;weeks after treatment has been stopped.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is not known whether everolimus is excreted in human milk. In animal studies, everolimus and/or its metabolites were readily transferred into the milk of lactating rats. Therefore, women who are taking Certican should not breast feed.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There are literature reports of reversible azoospermia and oligospermia in patients treated with mTOR inhibitors (see section 4.4, 4.8, and 5.3). The potential for everolimus to cause infertility in male and female patients is unknown, however, male infertility and secondary amenorrhoea have been observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies of the effects on the ability to drive and use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>a) Summary of the safety profile</u></p><p>The frequencies of adverse reactions listed below are derived from analysis of the 12-month incidences of events reported in multicentre, randomised, controlled trials investigating Certican in combination with calcineurin inhibitors (CNI) and corticosteroids in adult transplant recipients. All but two of the trials (in renal transplantation) included non-Certican, CNI-based standard-therapy arms. Certican combined with ciclosporin was studied in five trials in renal transplant recipients totalling 2,497 patients (including two studies without a non-Certican control group), and three trials in heart transplant recipients totalling 1,531 patients (ITT populations, see section 5.1).</p><p>&nbsp;</p><p>Certican combined with tacrolimus was studied in one trial, which included 719 liver transplant recipients (ITT population, see section 5.1).</p><p>&nbsp;</p><p>The most common events are: infections, anaemia, hyperlipidaemia, new onset of diabetes mellitus, insomnia, headache, hypertension, cough, constipation, nausea, peripheral oedema, impaired healing (including pleural and pericardial effusion).</p><p>&nbsp;</p><p>The occurrence of the adverse events may depend on the immunosuppressive regimen (i.e. degree and duration). In the studies combining Certican with ciclosporin, elevated serum creatinine was observed more frequently in patients administered Certican in combination with full-dose ciclosporin for microemulsion than in control patients. The overall incidence of adverse events was lower with reduced-dose ciclosporin for microemulsion (see section 5.1).</p><p>&nbsp;</p><p>The safety profile of Certican administered with reduced-dose ciclosporin was similar to that described in the 3 pivotal studies in which full-dose ciclosporin was administered, except that elevation of serum creatinine was less frequent, and mean and median serum creatinine values were lower, than in the Phase&nbsp;III studies.</p><p>&nbsp;</p><p><u>b) Tabulated summary of adverse reactions</u></p><p>Table 4 contains adverse drug reactions possibly or probably related to Certican seen in Phase III clinical trials. Unless noted otherwise, these disorders have been identified by an increased incidence in the Phase III studies comparing Certican-treated patients with patients on a non-Certican, standard-therapy regimen, or the same incidence in case the event is a known ADR of the comparator MPA in renal and heart transplant studies (see section 5.1). Except where noted otherwise, the adverse reaction profile is relatively consistent across all transplant indications. It is compiled according to MedDRA standard organ classes.</p><p>&nbsp;</p><p><em>Adverse reactions are listed according to their frequencies, which are defined as: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000).</em></p><p>&nbsp;</p><p><strong>Table </strong><strong>4 </strong><strong>Adverse drug reactions possibly or probably related to Certican</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body system</strong></p></td><td style="vertical-align:top"><p><strong>Incidence</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Infections (viral, bacterial, fungal), upper respiratory tract infection, lower respiratory tract and lung infections (including pneumonia)<sup>1</sup>, urinary tract infections<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Sepsis, wound infection</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Malignant or unspecified tumours, malignant and unspecified skin neoplasms</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Lymphomas/post-transplant lymphoproliferative disorders (PTLD)</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Leukopaenia, anaemia/erythropenia, thrombocytopenia<sup>1</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pancytopenia, thrombotic microangiopathies (including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypogonadism male (testosterone decreased, FSH and LH increased)</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hyperlipidaemia (cholesterol and triglycerides), new onset diabetes mellitus, hypokalaemia</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Insomnia, anxiety</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Pericardial effusion<sup>3</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hypertension, venous thromboembolic events</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Lymphocoele<sup>4</sup>, epistaxis,&nbsp; renal graft thrombosis</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Pleural effusion<sup>1</sup>, cough<sup>1</sup>, dyspnoea<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Interstitial lung disease<sup>5</sup></p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Abdominal pain, diarrhoea ,nausea, vomiting</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pancreatitis, stomatitis/mouth ulceration, oropharyngeal pain</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Non infectious hepatitis, jaundice</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Angiooedema<sup>6</sup>, acne, rash</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Myalgia, arthralgia</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Proteinuria<sup>2</sup>, renal tubular necrosis<sup>7</sup></p></td></tr><tr><td><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Erectile dysfunction, menstrual disorder (including amenorrhoea and menorrhagia)</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Ovarian cyst</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Peripheral oedema, pain, healing impaired, pyrexia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Incisional hernia</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hepatic enzyme abnormal<sup>8</sup></p></td></tr></tbody></table><p><sup>1</sup>common in renal and liver transplantation</p><p><sup>2</sup>common in cardiac and liver transplantation</p><p><sup>3</sup>in cardiac transplantation</p><p><sup>4</sup>in renal and cardiac transplantation<sup>5</sup>the SMQ-based search for ILD showed the frequency of ILD in the clinical trials. This broad search also included cases caused by related events, e.g. by infections. The frequency category given here is derived from the medical review of the known cases.</p><p><sup>6</sup>predominantly in patients receiving concomitant ACE inhibitors</p><p><sup>7</sup>in renal transplantation</p><p><sup>8</sup>&gamma;-GT, AST, ALT elevated</p><p><u>&nbsp;</u></p><p><u>c) Description of selected adverse reactions</u></p><p>As preclinical toxicology studies have shown that everolimus can reduce spermatogenesis, male infertility must be considered a potential risk of prolonged Certican therapy. There are literature reports of reversible azoospermia and oligospermia in patients treated with mTOR inhibitors.</p><p>&nbsp;</p><p>In controlled clinical trials in which a total of 3,256 patients receiving Certican in combination with other immunosuppressants were monitored for at least 1 year, a total of 3.1% developed malignancies, with 1.0% developing skin malignancies and 0.60% developing lymphomas or lymphoproliferative disorders.</p><p>&nbsp;</p><p>Cases of interstitial lung disease, implying lung intraparenchymal inflammation (pneumonitis) and/or fibrosis of non-infectious aetiology, some fatal, have occurred in patients receiving rapamycin and derivatives, including Certican. Mostly, the condition resolves after discontinuation of Certican and/or addition of glucocorticoids. However, fatal cases have also occurred.</p><p>&nbsp;</p><p><u>d) Adverse drug reactions from post-marketing spontaneous reports</u></p><p>The following adverse drug reactions have been derived from post-marketing experience with Certican via spontaneous case reports and literature cases. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency, which is therefore categorised as not known. Adverse drug reactions are listed according to system organ classes in MedDRA. Within each system organ class, ADRs are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table&nbsp;5 </strong><strong>Adverse drug reactions from spontaneous reports and literature (frequency not known)</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Body system</strong></p></td><td style="vertical-align:top"><p><strong>Incidence</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Iron deficiency</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Leukocytoclastic vasculitis, lymphoedema</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td colspan="2" style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Pulmonary alveolar proteinosis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td colspan="2" style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Erythroderma</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety information in children and adolescents is based on the data of 36-months in renal and 24-months in hepatic paediatric transplant patients (see section 5.1).</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions </u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions &nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong>&nbsp;</strong></p><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Saudi Arabia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>&nbsp;</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In animal studies, everolimus showed low acute toxic potential. No lethality or severe toxicity was observed after single oral doses of 2000&nbsp;mg/kg (limit test) in either mice or rats.</p><p>&nbsp;</p><p>Reported experience with overdose in humans is very limited; there is a single case of accidental ingestion of 1.5&nbsp;mg everolimus in a 2-year-old child where no adverse events were observed. Single doses up to 25&nbsp;mg have been administered to transplant patients with acceptable acute tolerability.</p><p>&nbsp;</p><p>General supportive measures should be initiated in all cases of overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: selective immunosuppressive agents. ATC code: L04AA18.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Everolimus, a proliferation signal inhibitor, prevents allograft rejection in rodent and non-human primate models of allotransplantation. It exerts its immunosuppressive effect by inhibiting the proliferation, and thus clonal expansion, of antigen-activated T cells, which is driven by T cell-specific interleukins, e.g. interleukin-2 and interleukin-15. Everolimus inhibits an intracellular signalling pathway, which is triggered upon binding of these T cell growth factors to their respective receptors, and which normally leads to cell proliferation. The blockage of this signal by everolimus leads to an arrest of the cells at the G<sub>1</sub> stage of the cell cycle.</p><p>&nbsp;</p><p>At the molecular level, everolimus forms a complex with the cytoplasmic protein FKBP-12. In the presence of everolimus, the growth factor-stimulated phosphorylation of the p70 S6 kinase is inhibited. Since p70 S6 kinase phosphorylation is under the control of FRAP (also called mTOR), this finding suggests that the everolimus-FKBP-12 complex binds to and thus interferes with the function of FRAP. FRAP is a key regulatory protein that governs cell metabolism, growth and proliferation; disabling FRAP function thus explains the cell cycle arrest caused by everolimus.</p><p>&nbsp;</p><p>Everolimus thus has a different mode of action to ciclosporin. In preclinical models of allotransplantation, the combination of everolimus and ciclosporin was more effective than either compound alone.</p><p>&nbsp;</p><p>The effect of everolimus is not restricted to T cells. It inhibits growth factor-stimulated proliferation of hematopoietic as well as non-hematopoietic cells in general, such as vascular smooth muscle cells. Growth factor-stimulated vascular smooth muscle cell proliferation, triggered by injury to endothelial cells and leading to neointima formation, plays a key role in the pathogenesis of chronic rejection. Preclinical studies with everolimus have shown inhibition of neointima formation in a rat aorta allotransplantation model.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><em>Renal transplantation</em></p><p>Certican in fixed doses of 1.5&nbsp;mg/day and 3&nbsp;mg/day, in combination with standard doses of ciclosporin for microemulsion and corticosteroids, was investigated in two Phase III <em>de novo</em> adult renal transplant trials (B201 and B251). Mycophenolate mofetil (MMF) 1&nbsp;g <em>b.i.d</em> was used as comparator. The co-primary composite endpoints were efficacy failure (biopsy-proven acute rejection, graft loss, death or loss to follow-up) at 6&nbsp;months, and graft loss, death or loss to follow-up at 12&nbsp;months. Certican was, overall, non-inferior to MMF in these trials. The incidence of biopsy-proven acute rejection at 6 months in the B201 study was 21.6%, 18.2%, and 23.5% for the Certican 1.5&nbsp;mg/day, Certican 3&nbsp;mg/day and MMF groups, respectively. In study B251, the incidences were 17.1%, 20.1%, and 23.5% for the Certican 1.5&nbsp;mg/day, Certican 3&nbsp;mg/day and MMF groups, respectively.</p><p>&nbsp;</p><p>Reduced allograft function with elevated serum creatinine was observed more frequently among subjects using Certican in combination with full-dose ciclosporin for microemulsion than in MMF patients. This effect suggests that Certican increases ciclosporin nephrotoxicity. Drug concentration-pharmacodynamic analysis showed that renal function was not impaired with reduced exposure to ciclosporin, while conserving efficacy for as long as the blood trough everolimus concentration was maintained above 3&nbsp;ng/ml. This concept was subsequently confirmed in two further Phase III studies (A2306 and A2307, including 237 and 256&nbsp;patients, respectively), which evaluated the efficacy and safety of Certican 1.5&nbsp;mg and 3&nbsp;mg per day (initial dosing; subsequent dosing based on target trough concentration &ge;3&nbsp;ng/ml) in combination with reduced exposure to ciclosporin. In both studies, renal function was preserved without compromising efficacy. In these studies, however, there was no non-Certican comparative arm. A Phase III, multicentre, randomised, open-label, controlled trial (A2309) has been completed in which 833 <em>de novo</em> renal transplant recipients were randomised to one of two Certican regimens, differing by dosage, and combined with reduced-dose ciclosporin or a standard regimen of sodium mycophenolate (MPA) + ciclosporin, and treated for 12&nbsp;months. All patients received induction therapy with basiliximab pre-transplant, and on Day&nbsp;4 post-transplant. Steroids were given as required post-transplant.</p><p>&nbsp;</p><p>Starting dosages in the two Certican groups were 1.5&nbsp;mg/d and 3&nbsp;mg/d, given in two divided doses, subsequently modified from Day&nbsp;5 onwards to maintain target blood trough everolimus concentrations of 3-8&nbsp;ng/ml and 6‑12&nbsp;ng/ml, respectively. Sodium mycophenolate dosage was 1.44&nbsp;g/d. Ciclosporin dosages were adapted to maintain target blood trough concentration windows as shown in Table6. The actual measured values for blood concentrations of everolimus and ciclosporin (C<sub>0</sub> and C2) are shown in Table7.</p><p>&nbsp;</p><p>Although the higher-dosage Certican regimen was as effective as the lower-dosage regimen, the overall safety was poorer, and so the higher-dosage regimen is not recommended.</p><p>&nbsp;</p><p>The lower-dosage regimen for Certican is recommended (see section 4.2).</p><p>&nbsp;</p><p><strong>Table&nbsp;6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study A2309: Target ciclosporin blood trough concentration windows</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:594px"><tbody><tr><td style="vertical-align:top"><p><strong>Target ciclosporin C<sub>0</sub> (ng/</strong><strong>ml</strong><strong>)</strong></p></td><td style="vertical-align:top"><p><strong>Mo 1</strong></p></td><td style="vertical-align:top"><p><strong>Mo 2-3</strong></p></td><td style="vertical-align:top"><p><strong>Mo 4-5</strong></p></td><td style="vertical-align:top"><p><strong>Mo 6-12</strong></p></td></tr><tr><td style="vertical-align:top"><p>Certican groups</p></td><td style="vertical-align:top"><p>100-200</p></td><td style="vertical-align:top"><p>75-150</p></td><td style="vertical-align:top"><p>50-100</p></td><td style="vertical-align:top"><p>25-50</p></td></tr><tr><td style="vertical-align:top"><p>MPA group</p></td><td style="vertical-align:top"><p>200-300</p></td><td style="vertical-align:top"><p>100-250</p></td><td style="vertical-align:top"><p>100-250</p></td><td style="vertical-align:top"><p>100-250</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table 7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study A2309: Measured trough blood concentrations of ciclosporin and everolimus</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Trough concentrations</strong></p><p><strong>(ng/ml)</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Certican groups</strong></p><p>(low-dose ciclosporin)</p></td><td colspan="2" style="vertical-align:top"><p><strong>MPA</strong></p><p>(standard ciclosporin)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Certican 1.5&nbsp;mg</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Certican 3.0&nbsp;mg</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Myfortic 1.44&nbsp;g</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Ciclosporin</strong></p></td><td style="vertical-align:top"><p><em>C<sub>o</sub> </em></p></td><td style="vertical-align:top"><p><em>C2 </em></p></td><td style="vertical-align:top"><p><em>C<sub>o</sub> </em></p></td><td style="vertical-align:top"><p><em>C2 </em></p></td><td style="vertical-align:top"><p><em>C<sub>o</sub> </em></p></td><td style="vertical-align:top"><p><em>C2 </em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Day&nbsp;7</strong></p></td><td style="vertical-align:top"><p>195 &plusmn; 106</p></td><td style="vertical-align:top"><p>847 &plusmn; 412</p></td><td style="vertical-align:top"><p>192 &plusmn; 104</p></td><td style="vertical-align:top"><p>718 &plusmn; 319</p></td><td style="vertical-align:top"><p>239 &plusmn; 130</p></td><td style="vertical-align:top"><p>934 &plusmn; 438</p></td></tr><tr><td style="vertical-align:top"><p><strong>Month&nbsp;1</strong></p></td><td style="vertical-align:top"><p>173 &plusmn; 84</p></td><td style="vertical-align:top"><p>770 &plusmn; 364</p></td><td style="vertical-align:top"><p>177 &plusmn; 99</p></td><td style="vertical-align:top"><p>762 &plusmn; 378</p></td><td style="vertical-align:top"><p>250 &plusmn; 119</p></td><td style="vertical-align:top"><p>992 &plusmn; 482</p></td></tr><tr><td style="vertical-align:top"><p><strong>Month&nbsp;3</strong></p></td><td style="vertical-align:top"><p>122 &plusmn; 53</p></td><td style="vertical-align:top"><p>580 &plusmn; 322</p></td><td style="vertical-align:top"><p>123 &plusmn; 75</p></td><td style="vertical-align:top"><p>548 &plusmn; 272</p></td><td style="vertical-align:top"><p>182 &plusmn; 65</p></td><td style="vertical-align:top"><p>821 &plusmn; 273</p></td></tr><tr><td style="vertical-align:top"><p><strong>Month&nbsp;6</strong></p></td><td style="vertical-align:top"><p>88 &plusmn; 55</p></td><td style="vertical-align:top"><p>408 &plusmn; 226</p></td><td style="vertical-align:top"><p>80 &plusmn; 40</p></td><td style="vertical-align:top"><p>426 &plusmn; 225</p></td><td style="vertical-align:top"><p>163 &plusmn; 103</p></td><td style="vertical-align:top"><p>751 &plusmn; 269</p></td></tr><tr><td style="vertical-align:top"><p><strong>Month&nbsp;9</strong></p></td><td style="vertical-align:top"><p>55&plusmn; 24</p></td><td style="vertical-align:top"><p>319 &plusmn; 172</p></td><td style="vertical-align:top"><p>51 &plusmn; 30</p></td><td style="vertical-align:top"><p>296 &plusmn; 183</p></td><td style="vertical-align:top"><p>149 &plusmn; 69</p></td><td style="vertical-align:top"><p>648 &plusmn; 265</p></td></tr><tr><td style="vertical-align:top"><p><strong>Month&nbsp;12</strong></p></td><td style="vertical-align:top"><p>55 &plusmn; 38</p></td><td style="vertical-align:top"><p>291 &plusmn; 155</p></td><td style="vertical-align:top"><p>49 &plusmn; 27</p></td><td style="vertical-align:top"><p>281 &plusmn; 198</p></td><td style="vertical-align:top"><p>137 &plusmn; 55</p></td><td style="vertical-align:top"><p>587&plusmn; 241</p></td></tr><tr><td style="vertical-align:top"><p><strong>Everolimus</strong></p></td><td colspan="2" style="vertical-align:top"><p>(Target C<sub>o</sub> 3-8)</p></td><td colspan="2" style="vertical-align:top"><p>(Target C<sub>o</sub> 6-12)</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Day&nbsp;7</p></td><td colspan="2" style="vertical-align:top"><p>4.5 &plusmn; 2.3</p></td><td colspan="2" style="vertical-align:top"><p>8.3 &plusmn; 4.8</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Month&nbsp;1</p></td><td colspan="2" style="vertical-align:top"><p>5.3 &plusmn; 2.2</p></td><td colspan="2" style="vertical-align:top"><p>8.6 &plusmn; 3.9</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Month&nbsp;3</p></td><td colspan="2" style="vertical-align:top"><p>6.0 &plusmn; 2.7</p></td><td colspan="2" style="vertical-align:top"><p>8.8 &plusmn; 3.6</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Month&nbsp;6</p></td><td colspan="2" style="vertical-align:top"><p>5.3 &plusmn; 1.9</p></td><td colspan="2" style="vertical-align:top"><p>8.0 &plusmn; 3.1</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Month&nbsp;9</p></td><td colspan="2" style="vertical-align:top"><p>5.3 &plusmn; 1.9</p></td><td colspan="2" style="vertical-align:top"><p>7.7 &plusmn; 2.6</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Month&nbsp;12</p></td><td colspan="2" style="vertical-align:top"><p>5.3 &plusmn; 2.3</p></td><td colspan="2" style="vertical-align:top"><p>7.9 &plusmn; 3.5</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Numbers are mean &plusmn; SD of measured values with C<sub>0</sub> = trough concentration, C2 = value 2 hours post-dose.</p></td></tr></tbody></table><p>&nbsp;</p><p>The primary efficacy endpoint was a composite failure variable (biopsy-proven acute rejection, graft loss, death or loss to follow-up). The outcome is shown in Table 8.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table&nbsp;8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study A2309: Composite and individual efficacy endpoints at 6 and 12&nbsp;months (incidence in ITT population)</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:627px"><thead><tr><td colspan="2" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="4" style="vertical-align:bottom"><p><strong>Certican 1.5 mg<br />N=277</strong><br /><strong>% (n)</strong></p></td><td colspan="4" style="vertical-align:bottom"><p><strong>Certican 3.0 mg<br />N=279</strong><br /><strong>% (n)</strong></p></td><td colspan="4" style="vertical-align:bottom"><p><strong>MPA&nbsp;1.44 g<br />N=277</strong><br /><strong>% (n)</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr></thead><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>6 mo</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>12 mo</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>6 mo</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>12 mo</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>6 mo</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>12 mo</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Composite endpoint</strong> (1<sup>0 </sup>criterion)</p></td><td colspan="2" style="vertical-align:top"><p><strong>19.1</strong> (53)</p></td><td colspan="2" style="vertical-align:top"><p><strong>25.3</strong> (70)</p></td><td colspan="2" style="vertical-align:top"><p><strong>16.8</strong> (47)</p></td><td colspan="2" style="vertical-align:top"><p><strong>21.5</strong> (60)</p></td><td colspan="2" style="vertical-align:top"><p><strong>18.8</strong> (52)</p></td><td colspan="2" style="vertical-align:top"><p><strong>24.2</strong> (67)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>Difference % <em>(Certican - MPA)</em></p><p>95% CI</p></td><td colspan="2"><p>0.4%</p><p>(-6.2, 6.9)</p></td><td colspan="2"><p>1.1%</p><p>(-6.1, 8.3)</p></td><td colspan="2"><p>-1.9%</p><p>(-8.3, 4.4)</p></td><td colspan="2"><p>-2.7%</p><p>(-9.7, 4.3)</p></td><td colspan="2"><p>-</p><p>-</p></td><td colspan="2"><p>-</p><p>-</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Individual endpoints</strong> (2<sup>0</sup><sup> </sup>criteria)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Treated BPAR</p></td><td colspan="2" style="vertical-align:top"><p><strong>10.8</strong> (30)</p></td><td colspan="2" style="vertical-align:top"><p><strong>16.2</strong> (45)</p></td><td colspan="2" style="vertical-align:top"><p><strong>10.0</strong> (28)</p></td><td colspan="2" style="vertical-align:top"><p><strong>13.3</strong> (37)</p></td><td colspan="2" style="vertical-align:top"><p><strong>13.7</strong> (38)</p></td><td colspan="2" style="vertical-align:top"><p><strong>17.0</strong> (47)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Graft loss</p></td><td colspan="2" style="vertical-align:top"><p><strong>4.0</strong> (11)</p></td><td colspan="2" style="vertical-align:top"><p><strong>4.3</strong> (12)</p></td><td colspan="2" style="vertical-align:top"><p><strong>3.9</strong> (11)</p></td><td colspan="2" style="vertical-align:top"><p><strong>4.7</strong> (13)</p></td><td colspan="2" style="vertical-align:top"><p><strong>2.9</strong> (8)</p></td><td colspan="2" style="vertical-align:top"><p><strong>3.2</strong> (9)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Death</p></td><td colspan="2" style="vertical-align:top"><p><strong>2.2</strong> (6)</p></td><td colspan="2" style="vertical-align:top"><p><strong>2.5</strong> (7)</p></td><td colspan="2" style="vertical-align:top"><p><strong>1.8</strong> (5)</p></td><td colspan="2" style="vertical-align:top"><p><strong>3.2</strong> (9)</p></td><td colspan="2" style="vertical-align:top"><p><strong>1.1</strong> (3)</p></td><td colspan="2" style="vertical-align:top"><p><strong>2.2</strong> (6)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Loss to follow-up</p></td><td colspan="2" style="vertical-align:top"><p><strong>3.6</strong> (10)</p></td><td colspan="2" style="vertical-align:top"><p><strong>4.3</strong> (12)</p></td><td colspan="2" style="vertical-align:top"><p><strong>2.5</strong> (7)</p></td><td colspan="2" style="vertical-align:top"><p><strong>2.5</strong> (7)</p></td><td colspan="2" style="vertical-align:top"><p><strong>1.8</strong> (5)</p></td><td colspan="2" style="vertical-align:top"><p><strong>3.2</strong> (9)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Combined endpoints</strong> (2<sup>0</sup><sup> </sup>criteria)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;&nbsp; Graft loss / Death</p></td><td colspan="2" style="vertical-align:top"><p><strong>5.8</strong> (16)</p></td><td colspan="2" style="vertical-align:top"><p><strong>6.5</strong> (18)</p></td><td colspan="2" style="vertical-align:top"><p><strong>5.7</strong> (16)</p></td><td colspan="2" style="vertical-align:top"><p><strong>7.5</strong> (21)</p></td><td colspan="2" style="vertical-align:top"><p><strong>4.0</strong> (11)</p></td><td colspan="3" style="vertical-align:top"><p><strong>5.4</strong> (15)</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;&nbsp; Graft loss / Death / Loss to FU</p></td><td colspan="2" style="vertical-align:top"><p><strong>9.4</strong> (26)</p></td><td colspan="2" style="vertical-align:top"><p><strong>10.8</strong> (30)</p></td><td colspan="2" style="vertical-align:top"><p><strong>8.2</strong> (23)</p></td><td colspan="2" style="vertical-align:top"><p><strong>10.0</strong> (28)</p></td><td colspan="2" style="vertical-align:top"><p><strong>5.8</strong> (16)</p></td><td colspan="3" style="vertical-align:top"><p><strong>8.7</strong> (24)</p></td></tr><tr><td colspan="15" style="vertical-align:top"><p>mo = months, 1<sup>0 </sup>= primary, 2<sup>0 </sup>= secondary, CI = confidence interval, non-inferiority margin was 10%<br />Composite endpoint: treated biopsy-proven acute rejection (BPAR), graft loss, death, or loss to follow-up (FU)</p></td><td><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>Changes in renal function, as shown by calculated glomerular filtration rate (GFR) using the MDRD formula, are shown in Table 9.</p><p>&nbsp;</p><p>Proteinuria was assessed at scheduled visits by spot analysis of urinary protein/creatinine (see Table10). A concentration effect was shown relating proteinuria levels to everolimus trough concentrations, particularly at C<sub>min</sub> values above 8&nbsp;ng/ml.</p><p>&nbsp;</p><p>Adverse events reported more frequently in the recommended (lower-dosage) Certican regimen than in the MPA control group have been included in Table4. A lower frequency of viral infections was reported for Certican-treated patients, resulting principally from lower reporting rates for CMV infection (0.7% vs. 5.95%) and BK virus infection (1.5% vs. 4.8%).</p><p>&nbsp;</p><p><strong>Table </strong><strong>9</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study A2309: Renal function (MDRD-calculated GFR) at 12&nbsp;months (ITT population)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Certican&nbsp;1.5&nbsp;mg<br />N=277</strong></p></td><td style="vertical-align:top"><p><strong>Certican&nbsp;3.0&nbsp;mg<br />N=279</strong></p></td><td style="vertical-align:top"><p><strong>MPA&nbsp;1.44&nbsp;g<br />N=277</strong></p></td></tr><tr><td style="vertical-align:top"><p>12-month mean GFR (ml/min/1.73&nbsp;m<sup>2</sup>)</p></td><td style="vertical-align:top"><p>54.6</p></td><td style="vertical-align:top"><p>51.3</p></td><td style="vertical-align:top"><p>52.2</p></td></tr><tr><td style="vertical-align:top"><p>Difference in mean (everolimus - MPA)</p><p>95% CI</p></td><td style="vertical-align:top"><p>2.37</p><p>(-1.7, 6.4)</p></td><td style="vertical-align:top"><p>-0.89</p><p>(-5.0, 3.2)</p></td><td style="vertical-align:top"><p>-</p><p>-</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>12-month GFR missing value imputation: graft loss = 0; death or loss to follow-up for renal function = LOCF1 (last-observation-carried-forward approach 1: End of Treatment (up to Month&nbsp;12)).</p><p>MDRD: modification of diet in renal disease</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study A2309: Urinary protein to creatinine ratio</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="4" style="vertical-align:bottom"><p><strong>Category of proteinuria (mg/mmol)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:bottom"><p><strong>Treatment</strong></p></td><td style="vertical-align:bottom"><p><strong>normal%</strong>(n)<br />(&lt;3.39)</p></td><td style="vertical-align:bottom"><p><strong>mild%</strong>(n)<br />(3.39-&lt;33.9)</p></td><td style="vertical-align:bottom"><p><strong>sub-</strong><strong>nephrotic</strong><strong>%</strong>(n)<br />(33.9-&lt;339)</p></td><td style="vertical-align:bottom"><p><strong>nephrotic</strong><strong>%</strong>(n) (&gt;339)</p></td></tr></thead><tbody><tr><td rowspan="3" style="vertical-align:top"><p><strong>Month&nbsp;12<br />(TED)</strong></p></td><td style="vertical-align:top"><p>Certican 1.5&nbsp;mg</p></td><td style="vertical-align:top"><p><strong>0.4</strong> (1)</p></td><td style="vertical-align:top"><p><strong>64.2</strong> (174)</p></td><td style="vertical-align:top"><p><strong>32.5</strong> (88)</p></td><td style="vertical-align:top"><p><strong>3.0</strong> (8)</p></td></tr><tr><td style="vertical-align:top"><p>Certican 3&nbsp;mg</p></td><td style="vertical-align:top"><p><strong>0.7</strong> (2)</p></td><td style="vertical-align:top"><p><strong>59.2</strong> (164)</p></td><td style="vertical-align:top"><p><strong>33.9</strong> (94)</p></td><td style="vertical-align:top"><p><strong>5.8</strong> (16)</p></td></tr><tr><td style="vertical-align:top"><p>MPA 1.44&nbsp;g</p></td><td style="vertical-align:top"><p><strong>1.8</strong> (5)</p></td><td style="vertical-align:top"><p><strong>73.1 </strong>(198)</p></td><td style="vertical-align:top"><p><strong>20.7</strong> (56)</p></td><td style="vertical-align:top"><p><strong>4.1</strong> (11)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>1&nbsp;mg/mmol = 8.84&nbsp;mg/g</p><p>TED: Treatment endpoint (Mo&nbsp;12 value or last observation carried forward)<strong> </strong></p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>Cardiac transplantation</em></p><p>In the Phase III cardiac study (B253), both Certican 1.5&nbsp;mg/day and 3&nbsp;mg/day, in combination with standard doses of ciclosporin for microemulsion and corticosteroids, was investigated vs. azathioprine (AZA) 1-3&nbsp;mg/kg/day. The primary endpoint was a composite of the incidence of acute rejection &sup3;ISHLT grade 3A, acute rejection associated with haemodynamic compromise, graft loss, patient death or loss to follow-up at 6, 12 and 24&nbsp;months. Both doses of Certican were superior to AZA at 6, 12 and 24&nbsp;months. The incidence of biopsy-proven acute rejection &sup3;ISHLT grade 3A at month 6 was 27.8% for the 1.5&nbsp;mg/day group, 19% for the 3&nbsp;mg/day group and 41.6% for the AZA group, respectively (p = 0.003 for 1.5&nbsp;mg vs. control, &lt;0.001 for 3&nbsp;mg vs. control).</p><p>&nbsp;</p><p>Based on coronary artery intravascular ultrasound data obtained from a subset of the study population, both Certican doses were statistically significantly more effective than AZA in preventing allograft vasculopathy (defined as an increase in maximum intimal thickness from baseline &sup3;0.5&nbsp;mm in at least one matched slice of an automated pullback sequence), an important risk factor for long-term graft loss.</p><p>&nbsp;</p><p>Elevated serum creatinine was observed more frequently among subjects using Certican in combination with full-dose ciclosporin for microemulsion than in AZA patients. These results indicated that Certican increases ciclosporin-induced nephrotoxicity.</p><p>&nbsp;</p><p>Study A2411 was a randomised, 12-month, open-label study comparing Certican in combination with reduced doses of ciclosporin microemulsion and corticosteroids to mycophenolic mofetil (MMF) and standard doses of ciclosporin microemulsion and corticosteroids in <em>de novo</em> cardiac transplant patients. Certican was initiated at 1.5&nbsp;mg/day and the dose was adjusted to maintain target blood everolimus trough concentrations of 3-8&nbsp;ng/ml. MMF dosage was initiated at 1500&nbsp;mg <em>b.i.d.</em> Ciclosporin microemulsion doses were adjusted to the following target trough concentrations (ng/ml):</p><p>&nbsp;</p><p><strong>Table 11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Target ciclosporin trough concentrations by month</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Target ciclosporin C</strong><strong><sub>0</sub></strong><strong> </strong></p></td><td><p>Mo 1</p></td><td><p>Mo 2</p></td><td><p>Mo 3-4</p></td><td><p>Mo 5-6</p></td><td><p>Mo 7-12</p></td></tr><tr><td style="vertical-align:top"><p><strong>Certican group</strong></p></td><td><p><strong>200-350</strong></p></td><td><p><strong>150-250</strong></p></td><td><p><strong>100-200</strong></p></td><td><p><strong>75-150</strong></p></td><td><p><strong>50-100</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>MMF group</strong></p></td><td><p>200-350</p></td><td><p>200-350</p></td><td><p>200-300</p></td><td><p>150-250</p></td><td><p>100-250</p></td></tr></tbody></table><p>&nbsp;</p><p>Actual blood concentrations measured are shown in Table 12.</p><p>&nbsp;</p><p>Table&nbsp;12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study A2411: Summary statistics for CsA blood concentrations* (mean &plusmn; SD)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Certican group<br />(N=91)</strong></p></td><td style="vertical-align:top"><p><strong>MMF group<br />(N=83)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Visit</strong></p></td><td style="vertical-align:top"><p><strong>C<sub>0</sub></strong></p></td><td style="vertical-align:top"><p><strong>C<sub>0</sub></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Day 4</strong></p></td><td style="vertical-align:top"><p>154 &plusmn; 71<br />n=79</p></td><td style="vertical-align:top"><p>155 &plusmn; 96<br />n=74</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mo 1</strong></p></td><td style="vertical-align:top"><p>245 &plusmn; 99<br />n=76</p></td><td style="vertical-align:top"><p>308 &plusmn; 96<br />n=71</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mo 3</strong></p></td><td style="vertical-align:top"><p>199 &plusmn; 96<br />n=70</p></td><td style="vertical-align:top"><p>256 &plusmn; 73<br />n=70</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mo 6</strong></p></td><td style="vertical-align:top"><p>157 &plusmn; 61<br />n=73</p></td><td style="vertical-align:top"><p>219 &plusmn; 83<br />n=67</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mo 9</strong></p></td><td style="vertical-align:top"><p>133 &plusmn; 67<br />n=72</p></td><td style="vertical-align:top"><p>187 &plusmn; 58<br />n=64</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mo 12</strong></p></td><td style="vertical-align:top"><p>110 &plusmn; 50<br />n=68</p></td><td style="vertical-align:top"><p>180 &plusmn; 55<br />n=64</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*:whole blood trough concentrations (C<sub>0</sub>)</p></td></tr></tbody></table><p>&nbsp;</p><p>Changes in renal function are shown in Table 13. Efficacy outcome is shown in Table 14.</p><p>&nbsp;</p><p>Table 13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study A2411: Changes in creatinine clearance during study (patients with paired values)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Estimated creatinine clearance (Cockcroft-Gault)*<br />ml/mn</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p><strong>Baseline</strong></p><p><strong>Mean (&plusmn; SD)</strong></p></td><td><p><strong>Value at timepoint</strong></p><p><strong>Mean (&plusmn; SD)</strong></p></td><td><p><strong>Difference between groups</strong></p><p><strong>Mean (95% CI)</strong></p></td></tr><tr><td rowspan="2"><p>Month&nbsp;1</p></td><td style="vertical-align:top"><p>Certican (n=87)</p></td><td><p>73.8 (&plusmn; 27.8)</p></td><td><p>68.5 (&plusmn; 31.5)</p></td><td rowspan="2"><p>-7.3</p><p>(-18.1, 3.4)</p></td></tr><tr><td style="vertical-align:top"><p>MMF (n=78)</p></td><td><p>77.4 (&plusmn; 32.6)</p></td><td><p>79.4 (&plusmn; 36.0)</p></td></tr><tr><td rowspan="2"><p>Month&nbsp;6</p></td><td style="vertical-align:top"><p>Certican (n=83)</p></td><td><p>74.4 (&plusmn; 28.2)</p></td><td><p>65.4 (&plusmn; 24.7)</p></td><td rowspan="2"><p>-5.0</p><p>(-13.6, 2.9)</p></td></tr><tr><td style="vertical-align:top"><p>MMF (n=72)</p></td><td><p>76.0 (&plusmn; 31.8)</p></td><td><p>72.4 (&plusmn; 26.4)</p></td></tr><tr><td rowspan="2"><p>Month&nbsp;12</p></td><td style="vertical-align:top"><p>Certican (n=71)</p></td><td><p>74.8 (&plusmn; 28.3)</p></td><td><p>68.7 (&plusmn; 27.7)</p></td><td rowspan="2"><p>-1.8</p><p>(-11.2, 7.5)</p></td></tr><tr><td style="vertical-align:top"><p>MMF (n=71)</p></td><td><p>76.2 (&plusmn; 32.1)</p></td><td><p>71.9 (&plusmn; 30.0)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>* includes patients with value at both baseline and visit</p></td></tr></tbody></table><p>&nbsp;</p><p>Table&nbsp;14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study A2411: Efficacy event rates (incidence in ITT population)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Efficacy endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Certican<br />n=92</strong></p></td><td style="vertical-align:top"><p><strong>MMF<br />n=84</strong></p></td><td style="vertical-align:top"><p><strong>Difference in event rates</strong></p><p><strong>Mean (95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>At 6&nbsp;months</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Biopsy-proven acute rejection &ge; ISHLT grade 3A</p></td><td><p>18 (19.6%)</p></td><td><p>23 (27.4%)</p></td><td><p>-7.8 (-20.3, 4.7)</p></td></tr><tr><td style="vertical-align:top"><p>Composite efficacy failure *</p></td><td><p>26 (28.3%)</p></td><td><p>31 (36.9%)</p></td><td><p>-8.6 (-22.5, 5.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>At 12&nbsp;months</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Biopsy-proven acute rejection &ge; ISHLT grade 3A</p></td><td><p>21 (22.8%)</p></td><td><p>25 (29.8%)</p></td><td><p>-6.9 (-19.9, 6.1)</p></td></tr><tr><td style="vertical-align:top"><p>Composite efficacy failure*</p></td><td><p>30 (32.6%)</p></td><td><p>35 (41.7%)</p></td><td><p>-9.1 (-23.3, 5.2)</p></td></tr><tr><td style="vertical-align:top"><p>Death or graft loss/re-transplant</p></td><td><p>10 (10.9%)</p></td><td><p>10 (11.9%)</p></td><td><p>-</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>* Composite efficacy failure: any of the following &ndash; acute rejection &ge; grade 3A, acute rejection with haemodynamic compromise, graft loss, death or loss to follow-up.</p></td></tr></tbody></table><p>&nbsp;</p><p>Study A2310 is a Phase III, multicentre, randomised, open-label study comparing two Certican/reduced-dose ciclosporin regimens against a standard mycophenolate mofetil (MMF)/ciclosporin regimen over 24&nbsp;months. The use of induction therapy was centre-specific (no-induction or basiliximab or thymoglobulin). All patients received corticosteroids.</p><p>&nbsp;</p><p>Starting doses in the Certican groups were 1.5&nbsp;mg/d and 3&nbsp;mg/d, and were adjusted to target blood trough everolimus concentrations of 3-8 ng/ml and 6-12&nbsp;ng/ml, respectively. The MMF dose was 3&nbsp;g/d. Ciclosporin dosages targeted the same blood trough concentration as in study A2411. Blood concentrations of everolimus and ciclosporin are shown in Table 15.</p><p>&nbsp;</p><p>Recruitment to the experimental, higher-dosage Certican treatment arm was prematurely discontinued because of an increased rate of fatalities, due to infection and cardiovascular disorders, occurring within the first 90&nbsp;days post-randomisation.</p><p>&nbsp;</p><p><strong>Table 15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study A2310: Measured trough blood concentrations of ciclosporin (CsA) and everolimus</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:548px"><tbody><tr><td style="vertical-align:top"><p><strong>Visit </strong><strong>w</strong><strong>indow</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Certican 1.5&nbsp;mg/reduced-dose CsA<br />N=279</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>MMF 3&nbsp;g/std-dose CsA</strong></p><p><strong>N=268</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>everolimus (C<sub>0&nbsp;ng</sub>/ml)</p></td><td colspan="4" style="vertical-align:top"><p>ciclosporin (C<sub>0&nbsp;ng</sub>/ml)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Day 4</p></td><td colspan="2" style="vertical-align:top"><p>5.7 (4.6)</p></td><td colspan="2" style="vertical-align:top"><p>153 (103)</p></td><td style="vertical-align:top"><p>151 (101)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Month 1</p></td><td colspan="2" style="vertical-align:top"><p>5.2 (2.4)</p></td><td colspan="2" style="vertical-align:top"><p>247 (91)</p></td><td style="vertical-align:top"><p>269 (99)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Month 3</p></td><td colspan="2" style="vertical-align:top"><p>5.4 (2.6)</p></td><td colspan="2" style="vertical-align:top"><p>209 (86)</p></td><td style="vertical-align:top"><p>245 (90)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Month 6</p></td><td colspan="2" style="vertical-align:top"><p>5.7 (2.3)</p></td><td colspan="2" style="vertical-align:top"><p>151 (76)</p></td><td style="vertical-align:top"><p>202 (72)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Month 9</p></td><td colspan="2" style="vertical-align:top"><p>5.5 (2.2)</p></td><td colspan="2" style="vertical-align:top"><p>117 (77)</p></td><td style="vertical-align:top"><p>176 (64)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Month 12</p></td><td colspan="2" style="vertical-align:top"><p>5.4 (2.0)</p></td><td colspan="2" style="vertical-align:top"><p>102 (48)</p></td><td style="vertical-align:top"><p>167 (66)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Numbers are the mean (standard deviation) of measured values of C<sub>0</sub>=trough concentration</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>Efficacy outcome at 12&nbsp;months is shown in Table 16.</p><p>&nbsp;</p><p><strong>Table&nbsp;16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study A2310: Incidence rates of efficacy endpoints by treatment group (ITT population &ndash; 12-month analysis)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:580px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Certican 1.5&nbsp;mg<br />N=279</strong></p></td><td style="vertical-align:top"><p><strong>MMF</strong><br /><strong>N=271</strong></p></td></tr><tr><td style="vertical-align:top"><p>Efficacy endpoints</p></td><td style="vertical-align:top"><p>n (%)</p></td><td style="vertical-align:top"><p>n (%)</p></td></tr><tr><td style="vertical-align:top"><p>Primary: Composite efficacy failure</p></td><td style="vertical-align:top"><p>99 (35.1)</p></td><td style="vertical-align:top"><p>91 (33.6)</p></td></tr><tr><td style="vertical-align:top"><p>- AR associated with HDC</p></td><td style="vertical-align:top"><p>11 (3.9)</p></td><td style="vertical-align:top"><p>7 (2.6)</p></td></tr><tr><td style="vertical-align:top"><p>- BPAR of ISHLT grade &sup3; 3A</p></td><td style="vertical-align:top"><p>63 (22.3)</p></td><td style="vertical-align:top"><p>67 (24.7)</p></td></tr><tr><td style="vertical-align:top"><p>- Death</p></td><td style="vertical-align:top"><p>22 (7.8)</p></td><td style="vertical-align:top"><p>13 (4.8)</p></td></tr><tr><td style="vertical-align:top"><p>- Graft loss/re-transplant</p></td><td style="vertical-align:top"><p>4 (1.4)</p></td><td style="vertical-align:top"><p>5 (1.8)</p></td></tr><tr><td style="vertical-align:top"><p>- Loss to follow-up</p></td><td style="vertical-align:top"><p>9 (3.2)</p></td><td style="vertical-align:top"><p>10 (3.7)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Composite efficacy failure: biopsy-proven acute rejection (BPAR) episodes of ISHLT grade &sup3; 3A, acute rejection (AR) associated with haemodynamic compromise (HDC), graft loss/re-transplant, death, or loss to follow-up.</p></td></tr></tbody></table><p>&nbsp;</p><p>The higher fatality rate in the Certican arm relative to the MMF arm was mainly the result of an increased rate of fatalities from infection in the first three months among Certican patients receiving thymoglobulin induction therapy. The imbalance in fatalities within the thymoglobulin subgroup was particularly evident among patients hospitalised prior to transplantation and with L-ventricular assistance devices (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p>Renal function over the course of study A2310, assessed by calculated glomerular filtration rate (GFR) using the MDRD formula, was 5.5&nbsp;ml/min/1.73&nbsp;m<sup>2</sup> (97.5% CI -10.9, -0.2) lower for the everolimus 1.5&nbsp;mg group at Month 12.</p><p>&nbsp;</p><p>This difference was mainly observed in centres where the mean ciclosporin concentrations were similar throughout the study period in patients receiving Certican and in patients randomised to the control arm. This finding underlines the importance of reducing the ciclosporin concentrations when combined with everolimus as indicated in Table&nbsp;17 (see also section 4.2):</p><p>&nbsp;</p><p><strong>Table 17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Target ciclosporin trough concentrations per month</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Target ciclosporin C<sub>0</sub></strong></p></td><td><p>Mo 1</p></td><td><p>Mo 2</p></td><td><p>Mo 3-4</p></td><td><p>Mo 5-6</p></td><td><p>Mo7-12</p></td></tr><tr><td style="vertical-align:top"><p><strong>Certican group</strong></p></td><td><p><strong>200-350</strong></p></td><td><p><strong>150-250</strong></p></td><td><p><strong>100-200</strong></p></td><td><p><strong>75-150</strong></p></td><td><p><strong>50-100</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>MMF group</strong></p></td><td><p>200-350</p></td><td><p>200-350</p></td><td><p>200-300</p></td><td><p>150-250</p></td><td><p>100-250</p></td></tr></tbody></table><p>&nbsp;</p><p>Additionally, the difference was mainly driven by a difference developed during the first month post-transplantation when patients are still in an unstable haemodynamic situation, possibly confounding the analysis of renal function. Thereafter, the decrease in mean GFR from Month&nbsp;1 to Month&nbsp;12 was significantly smaller in the everolimus group than in the control group (-6.4 vs. -13.7&nbsp;ml/min, p=0.002).</p><p>&nbsp;</p><p>Proteinuria, expressed as urinary protein: creatinine levels measured in spot urine samples, tended to be higher in the Certican-treated patients. Sub-nephrotic values were observed in 22% of the patients receiving Certican compared to MMF patients (8.6%). Nephrotic levels were also reported (0.8%), representing 2&nbsp;patients in each treatment group (see section 4.4).</p><p>&nbsp;</p><p>The adverse reactions for the everolimus 1.5&nbsp;mg group in Study A2310 are consistent with the adverse drug reactions presented in Table4. A lower rate of viral infections was reported for Certican-treated patients, resulting principally from a lower reporting rate for CMV infection compared to MMF (7.2% vs. 19.4%).</p><p><em>&nbsp;</em></p><p><em>Hepatic transplantation</em></p><p>In the Phase III adult hepatic transplant study (H2304), reduced exposure tacrolimus and Certican 1.0&nbsp;mg twice daily was administered to patients, with the initial Certican dose 4&nbsp;weeks after transplantation, and was investigated versus standard exposure tacrolimus. Certican was dose adjusted to maintain target blood everolimus trough concentrations between 3-8&nbsp;ng/ml for the Certican + reduced tacrolimus arm. Tacrolimus doses were subsequently adjusted to achieve target trough concentrations between 3-5&nbsp;ng/ml during 12&nbsp;months in the Certican + reduced tacrolimus arm.</p><p>&nbsp;</p><p>Only 2.6% of study participants in H2304 were black so this study provides only limited efficacy and safety data on this population (see section 4.2)</p><p>&nbsp;</p><p>Overall, in the 12-month analysis, the incidence of the composite endpoint (tBPAR, graft loss or death) was lower in the Certican + reduced tacrolimus arm (6.7%) compared to the tacrolimus control arm (9.7%) and consistent results were observed at 24&nbsp;months (see Table&nbsp;18).</p><p>&nbsp;</p><p>The results of individual components of the composite endpoint are shown in Table 19.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Table&nbsp;18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study H2304: Comparison between treatment groups for Kaplan-Meier incidence rates of primary efficacy endpoints (ITT population &ndash; 12 and 24-month analysis)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td rowspan="2"><p><strong>Statistic</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>EVR+Reduced TAC<br />N=245</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>TAC control<br />N=243</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>12-month</strong></p></td><td><p><strong>24-month</strong></p></td><td style="vertical-align:top"><p><strong>12-month</strong></p></td><td><p><strong>24-month</strong></p></td></tr><tr><td><p>Number of composite efficacy failures (tBPAR, graft loss or death) from randomisation till Month&nbsp;24/12</p></td><td><p>16</p></td><td><p>24</p></td><td><p>23</p></td><td><p>29</p></td></tr><tr><td><p>KM estimate of incidence rate of composite efficacy failure (tBPAR*, graft loss or death) at Month 24/12</p></td><td><p>6.7%</p></td><td><p>10.3%</p></td><td><p>9.7%</p></td><td><p>12.5%</p></td></tr><tr><td><p>Difference in KM estimates (vs. control)</p></td><td><p>-3.0%</p></td><td><p>2.2%</p></td><td><p><strong>&nbsp;</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>97.5% CI for difference</p></td><td><p>(-8.7%, 2.6%)</p></td><td><p>(-8.8%, 4.4%)</p></td><td><p><strong>&nbsp;</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>P-value Z-test (EVR+Reduced TAC - Control = 0)</p><p>(No difference test)</p></td><td><p>0.230</p></td><td><p>0.452</p></td><td><p><strong>&nbsp;</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>P-value* Z-test (EVR+Reduced TAC - Control &ge;0.12)</p><p>(Non-inferiority test)</p></td><td><p>&lt;0.001</p></td><td><p>&lt;0.001</p></td><td><p><strong>&nbsp;</strong></p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>*tBPAR = treated biopsy-proven acute rejection</p><p>&nbsp;</p><p>Table&nbsp;19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study H2304: Comparison between treatment groups for incidence rates of secondary efficacy endpoints (ITT population &ndash; 12 and 24-month analysis)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Efficacy endpoints</strong></p></td><td style="vertical-align:top"><p><strong>EVR/Reduced<br />TAC<br />N=245<br />n (%)</strong></p></td><td style="vertical-align:top"><p><strong>TAC<br />control<br />N=243<br />n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Risk diff. (95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>P-value*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Graft loss</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>12-month</p></td><td style="vertical-align:top"><p>6 (2.4)</p></td><td style="vertical-align:top"><p>3 (1.2)</p></td><td style="vertical-align:top"><p>1.2 (-7.8, 10.2)</p></td><td style="vertical-align:top"><p>0.5038</p></td></tr><tr><td><p>24-month</p></td><td style="vertical-align:top"><p>9 (3.9)</p></td><td style="vertical-align:top"><p>7 (3.2)</p></td><td style="vertical-align:top"><p>0.8% (-3.2, 4.7)</p></td><td style="vertical-align:top"><p>0.661</p></td></tr><tr><td style="vertical-align:top"><p>Death</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>12-month</p></td><td style="vertical-align:top"><p>9 (3.7)</p></td><td style="vertical-align:top"><p>6 (2.5)</p></td><td style="vertical-align:top"><p>1.2 (-7.8, 10.1)</p></td><td style="vertical-align:top"><p>0.6015</p></td></tr><tr><td><p>24-month</p></td><td style="vertical-align:top"><p>12 (5.2)</p></td><td style="vertical-align:top"><p>10 (4.4)</p></td><td style="vertical-align:top"><p>0.8% (-3.7, 5.2)</p></td><td style="vertical-align:top"><p>0.701</p></td></tr><tr><td style="vertical-align:top"><p>BPAR<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>12-month</p></td><td style="vertical-align:top"><p>10 (4.1)</p></td><td style="vertical-align:top"><p>26 (10.7)</p></td><td style="vertical-align:top"><p>-6.6 (-11.2, -2.0)</p></td><td style="vertical-align:top"><p>0.0052</p></td></tr><tr><td><p>24-month</p></td><td style="vertical-align:top"><p>14 (6.1)</p></td><td style="vertical-align:top"><p>30 (13.3)</p></td><td style="vertical-align:top"><p>-7.2% (-13.5, -0.9)</p></td><td style="vertical-align:top"><p>0.010</p></td></tr><tr><td style="vertical-align:top"><p>tBPAR<sup>2</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>12-month</p></td><td style="vertical-align:top"><p>7 (2.9)</p></td><td style="vertical-align:top"><p>17 (7.0)</p></td><td style="vertical-align:top"><p>-4.1 (-8.0, -0.3)</p></td><td style="vertical-align:top"><p>0.0345</p></td></tr><tr><td><p>24-month</p></td><td style="vertical-align:top"><p>11 (4.8)</p></td><td style="vertical-align:top"><p>18 (7.7)</p></td><td style="vertical-align:top"><p>-2.9% (-7.9, 2.2)</p></td><td style="vertical-align:top"><p>0.203</p></td></tr></tbody></table><p>&nbsp;</p><p>1. BPAR = biopsy-proven acute rejection; 2. tBPAR = treated biopsy-proven acute rejection</p><p>*All p-values are for two-sided test and were compared to 0.05 significance level.</p><p>&nbsp;</p><p>Comparison between treatment groups for change in eGFR (MDRD4) [ml/min/1.73&nbsp;m<sup>2</sup>] from time of randomisation (day&nbsp;30) to Month&nbsp;12&nbsp; and 24 demonstrated superior renal function for the Certican + reduced tacrolimus arm (see Table&nbsp;20).</p><p>&nbsp;</p><p>&nbsp;</p><p>Table&nbsp;20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study H2304: Comparison between treatment groups for eGFR (MDRD 4) at Month&nbsp;12 (ITT population &ndash; 12 and 24-month analysis)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="7" style="vertical-align:top"><p>Difference vs. control</p></td></tr><tr><td style="vertical-align:bottom"><p>Treatment</p></td><td style="vertical-align:bottom"><p>N</p></td><td style="vertical-align:bottom"><p>LS mean (SE)</p></td><td style="vertical-align:bottom"><p>LSM mean (SE)</p></td><td style="vertical-align:bottom"><p>97.5% CI</p></td><td style="vertical-align:bottom"><p>P-value(1)</p></td><td style="vertical-align:bottom"><p>P-value(2)</p></td></tr><tr><td style="vertical-align:top"><p>EVR+Reduced TAC</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>12-month</p></td><td style="vertical-align:top"><p>244</p></td><td style="vertical-align:top"><p>-2.23 (1.54)</p></td><td style="vertical-align:top"><p>8.50 (2.12)</p></td><td style="vertical-align:top"><p>(3.74, 13.27)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td><p>24-month</p></td><td style="vertical-align:top"><p>245</p></td><td style="vertical-align:top"><p>-7.94 (1.53)</p></td><td style="vertical-align:top"><p>6.66 (2.12)</p></td><td style="vertical-align:top"><p>(1.9, 11.42)</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td><td style="vertical-align:top"><p>0.0018</p></td></tr><tr><td style="vertical-align:top"><p>TAC control</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>12-month</p></td><td style="vertical-align:top"><p>243</p></td><td style="vertical-align:top"><p>-10.73 (1.54)</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>24-month</p></td><td style="vertical-align:top"><p>243</p></td><td style="vertical-align:top"><p>-14.60 (1.54)</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>Least squares means, 97.5% confidence intervals and p-values are from an ANCOVA model containing treatment and HCV status as factors, and baseline eGFR as a covariate.</p><p>P-value (1): Non-inferiority test with NI margin = -6&nbsp;ml/min/1.73m<sup>2</sup>, at one-sided 0.0125&nbsp;level.</p><p>P-value (2): Superiority test at two-sided 0.025&nbsp;levels.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>In paediatric renal and hepatic transplant patients, Certican should not be used. The European Medicines Agency has waived the obligation to submit the results of studies with paediatric cardiac transplant patients (see section 4.2).</p><p>&nbsp;</p><p>In paediatric renal allograft recipients (1-18 years of age; n=106), Certican was assessed in a 12-month trial with 24 months additional follow-up. This multi-center, randomized, open-label trial with two parallel groups (1:1) evaluated the use of Certican in combination with reduced tacrolimus and corticosteroid withdrawal at 6 months post transplantation in comparison to mycophenolate mofetil with standard tacrolimus. At 12 months, the efficacy for Certican with reduced tacrolimus and steroid withdrawal was comparable to mycophenolate mofetil with standard tacrolimus [9.6% (5/52) vs 5.6% (3/54)] for the primary composite efficacy failure (CEF) endpoint of BPAR, graft loss and death. All of the events were BPAR; graft loss and death did not occur. At 36 months follow-up, the CEF endpoint was similar in both treatment groups, while treated BPAR occurred in five patients in each group. Graft loss was reported in one patient (2.1%) in the group receiving Certican with reduced tacrolimus versus two patients (3.8%) in the group receiving mycophenolate mofetil with standard tacrolimus. No deaths were reported during the study. Extrapolation from Certican adult kidney transplant data to Certican paediatric study data and literature showed that the efficacy composite endpoint was lower than that observed in adults.&nbsp; Renal function calculated by estimated glomerular filtration rate (eGFR) was comparable between both study groups.</p><p>&nbsp;</p><p>Altogether 35% (18/52) patients in the Certican group vs. 17% (9/54) in the control group were withdrawn from study therapy due to AEs/Infections. &nbsp;Most of the AEs/infections leading to premature discontinuation of study medication were singular events and were not reported in more than one patient. In the Certican with reduced tacrolimus group two patients were reported with post-transplant lymphoproliferative disease and one patient with hepatocellular carcinoma.</p><p>&nbsp;</p><p>In paediatric hepatic transplant recipients (month 1-18 years of age; n=56) receiving either a full-size liver allograft or a technically modified liver allograft from a deceased or living donor, Certican with reduced tacrolimus or ciclosporin was evaluated in a 24-month, multi-center, single arm study. &nbsp;Efficacy failure was defined as a composite endpoint (tBPAR, graft loss or death at 12 months). Out of 56 patients, two patients met the primary composite efficacy failure endpoint or any of its components. There were no deaths or graft losses over 24 months of treatment. An improvement in renal function, as measured by the gain in mean estimated glomerular filtration rate (eGFR) from randomization to 12-months was 6.3 mL/min/1.73m<sup>2</sup>. An improvement in renal function was also observed at 24-months, with an increase in mean eGFR from baseline of 4.5 mL/min/1.73m<sup>2</sup>.</p><p>&nbsp;</p><p>In paediatric hepatic transplant recipients, there was no negative impact in growth or sexual maturation observed. However, three main safety concerns were identified from the analysis of the safety in paediatric hepatic transplant recipients compared to adults and published literature: high rates of premature discontinuation of study medication, serious infections leading to hospitalization and PTLD. Incidence rates for PTLD in the 2 - &lt;18 years age group,&nbsp; and notably in EBV negative children under 2 years of age, were higher compared to adults and published literature. Based on the safety data the benefit/risk profile does not support recommendations for use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>After oral administration, peak everolimus concentrations occur 1 to 2&nbsp;hours post-dose. Everolimus blood concentrations are dose proportional over the dose range of 0.25 to 15&nbsp;mg in transplant patients. The relative bioavailability of the dispersible tablet compared with the tablet is 0.90 (90% CI 0.76-1.07) based on the AUC ratio.</p><p>&nbsp;</p><p><em>Food effect</em></p><p>Everolimus C<sub>max</sub> and AUC are reduced by 60% and 16% when the tablet formulation is given with a high-fat meal. To minimise variability, Certican should be taken consistently with or without food.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The blood-to-plasma ratio of everolimus is concentration-dependent, ranging from 17% to 73% over the range of 5 to 5,000&nbsp;ng/ml. Plasma protein binding is approximately 74% in healthy subjects and patients with moderate hepatic impairment. The distribution volume associated with the terminal phase (Vz/F) in maintenance renal transplant patients is 342&nbsp;&plusmn;&nbsp;107&nbsp;litres.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Everolimus is a substrate of CYP3A4 and P-glycoprotein. Following oral administration, it is the main circulating component in human blood. Six main metabolites of everolimus have been detected in human blood, including three monohydroxylated metabolites, two hydrolytic ring-opened products, and a phosphatidylcholine conjugate of everolimus. These metabolites were also identified in animal species used in toxicity studies, and showed approximately 100&nbsp;times less activity than everolimus itself. Hence, the parent substance is considered to contribute the majority of the overall pharmacological activity of everolimus.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>After a single dose of radiolabelled everolimus to transplant patients receiving ciclosporin, the majority (80%) of radioactivity was recovered from the faeces, and only a minor amount (5%) was excreted in urine. Parent drug was not detected in urine and faeces.</p><p>&nbsp;</p><p><u>Steady-state pharmacokinetics</u></p><p>Pharmacokinetics were comparable for kidney and heart transplant patients receiving everolimus twice daily simultaneously with ciclosporin for microemulsion. Steady-state is reached by day&nbsp;4 with an accumulation in blood concentrations of 2 to 3-fold compared with exposure after the first dose. T<sub>max</sub> occurs at 1 to 2&nbsp;hours post-dose. C<sub>max</sub> averages 11.1&nbsp;&plusmn;&nbsp;4.6 and 20.3&nbsp;&plusmn;&nbsp;8.0&nbsp;ng/ml and AUC averages 75&nbsp;&plusmn;&nbsp;31 and 131&nbsp;&plusmn;&nbsp;59&nbsp;ng.h/ml at 0.75 and 1.5&nbsp;mg <em>b.i.d.</em>, respectively. Pre-dose trough blood concentrations (C<sub>min</sub>) average 4.1&nbsp;&plusmn;&nbsp;2.1 and 7.1&nbsp;&plusmn;&nbsp;4.6 ng/ml at 0.75 and 1.5&nbsp;mg <em>b.i.d.</em>, respectively. Everolimus exposure remains stable over time in the first post-transplant year. C<sub>min</sub> is significantly correlated with AUC, yielding a correlation coefficient between 0.86 and 0.94. Based on a population pharmacokinetic analysis, oral clearance (CL/F) is 8.8&nbsp;litres/hour (27% interpatient variation) and the central distribution volume (Vc/F) is 110&nbsp;litres (36% interpatient variation). Residual variability in blood concentrations is 31%. The elimination half-life is 28&nbsp;&plusmn;&nbsp;7&nbsp;hours.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Hepatic impairment</em></p><p>Relative to the AUC of everolimus in subjects with normal hepatic function, the average AUC in 6&nbsp;patients with mild hepatic impairment (Child-Pugh Class A) was 1.6-fold higher; in two independently studied groups of 8 and 9&nbsp;patients with moderate hepatic impairment (Child-Pugh Class B), the average AUC was 2.1-fold and 3.3-fold higher, respectively; and in 6&nbsp;patients with severe hepatic impairment (Child-Pugh Class C), the average AUC was 3.6-fold higher.<strong> </strong>Mean half-lives were 52, 59 and 78&nbsp;hours in mild, moderate and severe hepatic impairment. The prolonged half-lives delay the time to reach steady-state everolimus blood concentrations.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Post-transplant renal impairment (C<sub>Cr</sub> range 11-107 ml/min) did not affect the pharmacokinetics of everolimus.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Fourteen paediatric <em>de novo</em> renal transplant patients (2 to 16&nbsp;years) received Certican dispersible tablets at a starting dose of 0.8&nbsp;mg/m<sup>2</sup> (maximum 1.5&nbsp;mg) twice daily with ciclosporin for microemulsion. Their doses were subsequently individualised based on therapeutic drug monitoring to maintain everolimus pre-dose trough concentrations &ge;3&nbsp;ng/ml. At steady state, the everolimus trough level was 6.2&nbsp;&plusmn;&nbsp;2.4&nbsp;ng/ml, C<sub>max</sub> was 18.2&nbsp;&plusmn;&nbsp;5.5&nbsp;ng/ml, and AUC was 118&nbsp;&plusmn;&nbsp;28&nbsp;ng.h/ml, which are comparable to adults receiving Certican targeted to similar pre-dose trough concentrations. The steady-state CL/F was 7.1&nbsp;&plusmn;&nbsp;1.7&nbsp;l/h/m<sup>2</sup> and the elimination half-life was 30&nbsp;&plusmn;&nbsp;11&nbsp;h in paediatric patients.</p><p>&nbsp;</p><p><em>Elderly patients</em></p><p>A limited reduction in everolimus oral clearance by 0.33% per year was estimated in adults (age range studied was 16-70&nbsp;years). No dose adjustment is considered necessary.</p><p>&nbsp;</p><p><em>Ethnicity</em></p><p>Based on a population pharmacokinetic analysis, oral clearance (CL/F) is, on average, 20% higher in black transplant patients. See section 4.2.</p><p>&nbsp;</p><p><u>Exposure-response relationships</u></p><p>The average everolimus trough concentration over the first 6&nbsp;months post-transplant was related to the incidence of biopsy-confirmed acute rejection and of thrombocytopenia in renal and cardiac transplant patients (see Table&nbsp;21). In hepatic transplant patients, the relationship between average everolimus trough concentrations and the incidence of biopsy-proven acute rejection is less well defined. No correlation between higher everolimus exposure and adverse events such as thrombocytopenia has been observed (see Table21).</p><p>&nbsp;</p><p><strong>Table&nbsp;21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exposure-response relationships for everolimus in transplant patients</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>Renal transplantation:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Trough concentration (ng/ml)</p></td><td style="vertical-align:top"><p>&le;3.4</p></td><td style="vertical-align:top"><p>3.5 - 4.5</p></td><td style="vertical-align:top"><p>4.6 - 5.7</p></td><td colspan="2" style="vertical-align:top"><p>5.8 - 7.7</p></td><td style="vertical-align:top"><p>7.8 - 15.0</p></td></tr><tr><td style="vertical-align:top"><p>Freedom from rejection</p></td><td style="vertical-align:top"><p>68%</p></td><td style="vertical-align:top"><p>81%</p></td><td style="vertical-align:top"><p>86%</p></td><td colspan="2" style="vertical-align:top"><p>81%</p></td><td style="vertical-align:top"><p>91%</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia<br />(&lt;100&nbsp;x&nbsp;10<sup>9</sup>/l)</p></td><td style="vertical-align:top"><p>10%</p></td><td style="vertical-align:top"><p>9%</p></td><td style="vertical-align:top"><p>7%</p></td><td colspan="2" style="vertical-align:top"><p>14%</p></td><td style="vertical-align:top"><p>17%</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Cardiac transplantation</strong>:</p></td></tr><tr><td style="vertical-align:top"><p>Trough concentration (ng/ml)</p></td><td style="vertical-align:top"><p>&le;3.5</p></td><td style="vertical-align:top"><p>3.6 - 5.3</p></td><td style="vertical-align:top"><p>5.4 - 7.3</p></td><td colspan="2" style="vertical-align:top"><p>7.4 - 10.2</p></td><td style="vertical-align:top"><p>10.3 - 21.8</p></td></tr><tr><td style="vertical-align:top"><p>Freedom from rejection</p></td><td style="vertical-align:top"><p>65%</p></td><td style="vertical-align:top"><p>69%</p></td><td style="vertical-align:top"><p>80%</p></td><td colspan="2" style="vertical-align:top"><p>85%</p></td><td style="vertical-align:top"><p>85%</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia<br />(&lt;75&nbsp;x&nbsp;10<sup>9</sup>/l)</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>6%</p></td><td colspan="2" style="vertical-align:top"><p>8%</p></td><td style="vertical-align:top"><p>9%</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Hepatic transplantation:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Trough concentration (ng/ml)</p></td><td style="vertical-align:top"><p>&le;3</p></td><td colspan="3" style="vertical-align:top"><p>3-8</p></td><td colspan="2" style="vertical-align:top"><p>&ge;8</p></td></tr><tr><td style="vertical-align:top"><p>Freedom from treated BPAR</p></td><td style="vertical-align:top"><p>88%</p></td><td colspan="3" style="vertical-align:top"><p>98%</p></td><td colspan="2" style="vertical-align:top"><p>92%</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia (&le;75&nbsp;x&nbsp;10<sup>9</sup>/l)</p></td><td style="vertical-align:top"><p>35%</p></td><td colspan="3" style="vertical-align:top"><p>13%</p></td><td colspan="2" style="vertical-align:top"><p>18%</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The preclinical safety profile of everolimus was assessed in mice, rats, minipigs, monkeys and rabbits. The major target organs were male and female reproductive systems (testicular tubular degeneration, reduced sperm content in epididymides and uterine atrophy) in several species, and, in rats only, lungs (increased alveolar macrophages) and eyes (lenticular anterior suture line opacities). Minor kidney changes were seen in the rat (exacerbation of age-related lipofuscin in tubular epithelium) and the mouse (exacerbation of background lesions). There was no indication of kidney toxicity in monkeys or minipigs.</p><p>&nbsp;</p><p>Spontaneously occurring background diseases (chronic myocarditis in the rat, Coxsackie virus infection in plasma and heart in monkeys, coccidial infestation of GI tract in minipigs, skin lesions in mice and monkeys) appeared to be exacerbated by treatment with everolimus. These findings were generally observed at systemic exposure concentrations within the range of therapeutic exposure or above, with the exception of findings in rats, which occurred below therapeutic exposure due to high tissue distribution.</p><p>&nbsp;</p><p>Ciclosporin in combination with everolimus caused higher systemic exposure to everolimus and increased toxicity. There were no new target organs in the rat. Monkeys showed haemorrhage and arteritis in several organs.</p><p>&nbsp;</p><p>In a male fertility study in rats, testicular morphology was affected at 0.5&nbsp;mg/kg and above, and sperm motility, sperm count and plasma testosterone levels were diminished at 5&nbsp;mg/kg, which is within the range of therapeutic exposure and caused a decrease in male fertility. There was evidence of reversibility. Female fertility was not affected, but everolimus crossed the placenta and was toxic to the conceptus. In rats, everolimus caused embryo/foetotoxicity at systemic exposure below the therapeutic exposure, which was manifested as mortality (pre-implantation loss) and reduced foetal weight. The incidence of skeletal variations and malformations at 0.3&nbsp;and 0.9&nbsp;mg/kg (e.g. sternal cleft) was increased. In rabbits, embryotoxicity was evident by an increase in late resorptions.</p><p>&nbsp;</p><p>Genotoxicity studies covering relevant genotoxicity endpoints showed no evidence of clastogenic or mutagenic activity. Administration of everolimus for up to 2 years did not indicate any oncogenic potential in mice and rats up to the highest doses, corresponding respectively to 8.6 and 0.3 times the estimated clinical exposure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Butylated hydroxytoluene (E321)</p><p>Magnesium stearate (E470 B)</p><p>Lactose monohydrate</p><p>Hypromellose Type 2910</p><p>Crospovidone Type A</p><p>Lactose anhydrous</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&ordm;C. Store in the original package in order to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Aluminium/polyamide/aluminium/PVC blister.</p><p>Packs containing 60 tablets.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
The Marketing Authorization Holder for this Product is Novartis Pharma AG. www.Novartis.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MHRA (09 June 2022)
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>